WO2012169649A1 - Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof - Google Patents
Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof Download PDFInfo
- Publication number
- WO2012169649A1 WO2012169649A1 PCT/JP2012/065052 JP2012065052W WO2012169649A1 WO 2012169649 A1 WO2012169649 A1 WO 2012169649A1 JP 2012065052 W JP2012065052 W JP 2012065052W WO 2012169649 A1 WO2012169649 A1 WO 2012169649A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- optionally
- substituted
- oxadiazol
- methyl
- Prior art date
Links
- 108091005482 5-HT4 receptors Proteins 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- -1 phenacyl group Chemical group 0.000 claims description 335
- 150000001875 compounds Chemical class 0.000 claims description 276
- 125000000217 alkyl group Chemical group 0.000 claims description 180
- 125000005843 halogen group Chemical group 0.000 claims description 152
- 125000003545 alkoxy group Chemical group 0.000 claims description 131
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 128
- 125000001424 substituent group Chemical group 0.000 claims description 104
- 125000001072 heteroaryl group Chemical group 0.000 claims description 103
- 125000003118 aryl group Chemical group 0.000 claims description 102
- 125000002950 monocyclic group Chemical group 0.000 claims description 100
- 125000000623 heterocyclic group Chemical group 0.000 claims description 99
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 96
- 125000002619 bicyclic group Chemical group 0.000 claims description 95
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 91
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 81
- 229910052757 nitrogen Inorganic materials 0.000 claims description 81
- 125000004043 oxo group Chemical group O=* 0.000 claims description 76
- 150000003839 salts Chemical class 0.000 claims description 76
- 125000001188 haloalkyl group Chemical group 0.000 claims description 72
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 68
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 66
- 125000004432 carbon atom Chemical group C* 0.000 claims description 61
- 125000002252 acyl group Chemical group 0.000 claims description 59
- 125000000081 (C5-C8) cycloalkenyl group Chemical class 0.000 claims description 57
- 125000000304 alkynyl group Chemical group 0.000 claims description 51
- 125000003342 alkenyl group Chemical group 0.000 claims description 49
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 49
- 229910052799 carbon Inorganic materials 0.000 claims description 48
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 47
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 46
- 125000003277 amino group Chemical class 0.000 claims description 46
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 45
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 44
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 40
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 34
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 32
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 30
- 125000004104 aryloxy group Chemical group 0.000 claims description 30
- 229920006395 saturated elastomer Polymers 0.000 claims description 27
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 26
- 229910052717 sulfur Inorganic materials 0.000 claims description 26
- 125000004434 sulfur atom Chemical group 0.000 claims description 26
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 24
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 23
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 22
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 19
- 208000024827 Alzheimer disease Diseases 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 16
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 11
- 238000009739 binding Methods 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 11
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 10
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 9
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 9
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 9
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 claims description 5
- 150000003413 spiro compounds Chemical class 0.000 claims description 5
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 239000000387 serotonin 5-HT4 receptor agonist Substances 0.000 claims description 3
- HOTSKDJTIYFOFX-UHFFFAOYSA-N 3-(3-ethyl-6-fluoroindazol-1-yl)-5-(1-propan-2-ylpiperidin-4-yl)-1,2,4-oxadiazole Chemical compound C12=CC(F)=CC=C2C(CC)=NN1C(N=1)=NOC=1C1CCN(C(C)C)CC1 HOTSKDJTIYFOFX-UHFFFAOYSA-N 0.000 claims description 2
- QNWXFSNRRTYHBM-UHFFFAOYSA-N 3-(3-ethyl-7-fluoroindazol-1-yl)-5-[1-(3-methoxypropyl)piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C1CCN(CCCOC)CC1 QNWXFSNRRTYHBM-UHFFFAOYSA-N 0.000 claims description 2
- VXZCTHDZGQPRNB-UHFFFAOYSA-N 3-(3-propan-2-ylindazol-1-yl)-5-(1-propylpiperidin-4-yl)-1,2,4-oxadiazole Chemical compound C1CN(CCC)CCC1C1=NC(N2C3=CC=CC=C3C(C(C)C)=N2)=NO1 VXZCTHDZGQPRNB-UHFFFAOYSA-N 0.000 claims description 2
- KVVMXWRFYAGASO-UHFFFAOYSA-N azetidine-1-carboxylic acid Chemical compound OC(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-N 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 2
- OUFSOXKXMOXXLL-OAHLLOKOSA-N 1-[3-[[(3r)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]azetidin-1-yl]-2-hydroxyethanone Chemical compound C([C@@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)C(C)C)CN1CC1CN(C(=O)CO)C1 OUFSOXKXMOXXLL-OAHLLOKOSA-N 0.000 claims 1
- PFDBLDXPCWBDIO-MRXNPFEDSA-N 1-[3-[[(3r)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]azetidin-1-yl]ethanone Chemical compound C([C@@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)C(C)C)CN1CC1CN(C(C)=O)C1 PFDBLDXPCWBDIO-MRXNPFEDSA-N 0.000 claims 1
- KVMDFFICDUBQIA-UHFFFAOYSA-N 3-(3-ethyl-6-fluoroindazol-1-yl)-5-[1-(3-methoxypropyl)piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=CC(F)=CC=C2C(CC)=NN1C(N=1)=NOC=1C1CCN(CCCOC)CC1 KVMDFFICDUBQIA-UHFFFAOYSA-N 0.000 claims 1
- CWNNWNSVQQXMIM-UHFFFAOYSA-N 3-(3-ethyl-7-fluoroindazol-1-yl)-5-[1-(1-methylsulfonylpiperidin-4-yl)piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C1CCN(S(C)(=O)=O)CC1 CWNNWNSVQQXMIM-UHFFFAOYSA-N 0.000 claims 1
- PBFWIRJENZTYLS-HNNXBMFYSA-N 3-(3-ethyl-7-fluoroindazol-1-yl)-5-[1-[[(3s)-1-methylsulfonylpyrrolidin-3-yl]methyl]piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C[C@@H]1CCN(S(C)(=O)=O)C1 PBFWIRJENZTYLS-HNNXBMFYSA-N 0.000 claims 1
- IHAYQKGJNWCNNG-UHFFFAOYSA-N 3-(3-ethylindazol-1-yl)-5-[1-(oxolan-2-ylmethyl)piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=CC=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1CC1CCCO1 IHAYQKGJNWCNNG-UHFFFAOYSA-N 0.000 claims 1
- KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 claims 1
- KHTBKDIVMIHRSN-UHFFFAOYSA-N methyl 4-[4-[3-(3-ethyl-6-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]piperidine-1-carboxylate Chemical compound C12=CC(F)=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C1CCN(C(=O)OC)CC1 KHTBKDIVMIHRSN-UHFFFAOYSA-N 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 abstract description 12
- 230000036961 partial effect Effects 0.000 abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 246
- 239000000243 solution Substances 0.000 description 159
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 135
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 132
- 239000000203 mixture Substances 0.000 description 126
- 238000006243 chemical reaction Methods 0.000 description 120
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 115
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 107
- 239000002904 solvent Substances 0.000 description 98
- 230000002829 reductive effect Effects 0.000 description 93
- 235000019439 ethyl acetate Nutrition 0.000 description 83
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 77
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 63
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 57
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 53
- 230000008569 process Effects 0.000 description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 45
- 239000012044 organic layer Substances 0.000 description 45
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 238000002360 preparation method Methods 0.000 description 39
- 238000010898 silica gel chromatography Methods 0.000 description 39
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 37
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 34
- 239000000706 filtrate Substances 0.000 description 33
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 30
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 30
- 239000002585 base Substances 0.000 description 30
- 239000002253 acid Substances 0.000 description 29
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- 239000012267 brine Substances 0.000 description 26
- 239000011259 mixed solution Substances 0.000 description 26
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 26
- 239000007858 starting material Substances 0.000 description 25
- 229910052938 sodium sulfate Inorganic materials 0.000 description 24
- 235000011152 sodium sulphate Nutrition 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 23
- 239000007864 aqueous solution Substances 0.000 description 22
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 22
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 21
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
- 150000008065 acid anhydrides Chemical class 0.000 description 19
- 229960004132 diethyl ether Drugs 0.000 description 19
- 206010010774 Constipation Diseases 0.000 description 18
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 18
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 18
- 239000013078 crystal Substances 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 14
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000001914 filtration Methods 0.000 description 13
- 125000006239 protecting group Chemical group 0.000 description 13
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 12
- 229910052801 chlorine Inorganic materials 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 11
- 239000000543 intermediate Substances 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 10
- 238000005804 alkylation reaction Methods 0.000 description 10
- 150000002170 ethers Chemical class 0.000 description 10
- 229940052303 ethers for general anesthesia Drugs 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- 235000011181 potassium carbonates Nutrition 0.000 description 10
- 238000005932 reductive alkylation reaction Methods 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- 239000008096 xylene Substances 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 9
- 150000001298 alcohols Chemical class 0.000 description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 9
- 229910052794 bromium Inorganic materials 0.000 description 9
- 239000012230 colorless oil Substances 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 9
- 150000008282 halocarbons Chemical class 0.000 description 9
- 229910052720 vanadium Inorganic materials 0.000 description 9
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 8
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 8
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 229940044601 receptor agonist Drugs 0.000 description 8
- 239000000018 receptor agonist Substances 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 8
- GYJZLYVSZDCEJK-UHFFFAOYSA-N 3-ethyl-6-fluoro-n'-hydroxyindazole-1-carboximidamide Chemical compound FC1=CC=C2C(CC)=NN(C(N)=NO)C2=C1 GYJZLYVSZDCEJK-UHFFFAOYSA-N 0.000 description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- DSRXQXXHDIAVJT-UHFFFAOYSA-N acetonitrile;n,n-dimethylformamide Chemical compound CC#N.CN(C)C=O DSRXQXXHDIAVJT-UHFFFAOYSA-N 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 150000004820 halides Chemical class 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 229960004592 isopropanol Drugs 0.000 description 7
- 150000002576 ketones Chemical class 0.000 description 7
- 239000012046 mixed solvent Substances 0.000 description 7
- 125000002757 morpholinyl group Chemical group 0.000 description 7
- 125000004193 piperazinyl group Chemical group 0.000 description 7
- 125000003386 piperidinyl group Chemical group 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 6
- 239000007818 Grignard reagent Substances 0.000 description 6
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 6
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 6
- 230000029936 alkylation Effects 0.000 description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 125000002393 azetidinyl group Chemical group 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 208000010643 digestive system disease Diseases 0.000 description 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 150000007530 organic bases Chemical class 0.000 description 6
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 6
- 235000015497 potassium bicarbonate Nutrition 0.000 description 6
- 239000011736 potassium bicarbonate Substances 0.000 description 6
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 150000004795 grignard reagents Chemical class 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 5
- 238000000691 measurement method Methods 0.000 description 5
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 4
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 4
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 4
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 4
- 125000006017 1-propenyl group Chemical group 0.000 description 4
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 4
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 4
- HLCPWBZNUKCSBN-UHFFFAOYSA-N 2-aminobenzonitrile Chemical compound NC1=CC=CC=C1C#N HLCPWBZNUKCSBN-UHFFFAOYSA-N 0.000 description 4
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 4
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 4
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 4
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 4
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 4
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 4
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 208000007882 Gastritis Diseases 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 description 4
- 239000002841 Lewis acid Substances 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 238000007333 cyanation reaction Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000006549 dyspepsia Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 4
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 238000007327 hydrogenolysis reaction Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 4
- 150000007517 lewis acids Chemical class 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 description 4
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- 235000010288 sodium nitrite Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 3
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 3
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 3
- 125000006023 1-pentenyl group Chemical group 0.000 description 3
- FCAJYRVEBULFKS-UHFFFAOYSA-N 2-(oxolan-2-yl)ethanol Chemical compound OCCC1CCCO1 FCAJYRVEBULFKS-UHFFFAOYSA-N 0.000 description 3
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 3
- 125000006026 2-methyl-1-butenyl group Chemical group 0.000 description 3
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 3
- 125000006031 2-methyl-3-butenyl group Chemical group 0.000 description 3
- 125000006024 2-pentenyl group Chemical group 0.000 description 3
- CJQNJRRDTPULTL-UHFFFAOYSA-N 3-azabicyclo[3.2.1]octane Chemical compound C1C2CCC1CNC2 CJQNJRRDTPULTL-UHFFFAOYSA-N 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- ICWGBAFJCUHSHX-UHFFFAOYSA-N 3-ethyl-6-fluoro-2h-indazole Chemical compound FC1=CC=C2C(CC)=NNC2=C1 ICWGBAFJCUHSHX-UHFFFAOYSA-N 0.000 description 3
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 3
- SNZSSCZJMVIOCR-UHFFFAOYSA-N 7-azabicyclo[2.2.1]heptane Chemical compound C1CC2CCC1N2 SNZSSCZJMVIOCR-UHFFFAOYSA-N 0.000 description 3
- DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical compound C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 241000792859 Enema Species 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 3
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000007920 enema Substances 0.000 description 3
- 229940095399 enema Drugs 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229940071870 hydroiodic acid Drugs 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- WZDHMXXBFCUFCD-UHFFFAOYSA-N indazole-1-carboximidamide Chemical compound C1=CC=C2N(C(=N)N)N=CC2=C1 WZDHMXXBFCUFCD-UHFFFAOYSA-N 0.000 description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- YNMRDSJIWFLYRG-UHFFFAOYSA-N n'-hydroxy-3-propan-2-ylindazole-1-carboximidamide Chemical compound C1=CC=C2C(C(C)C)=NN(C(N)=NO)C2=C1 YNMRDSJIWFLYRG-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000011369 resultant mixture Substances 0.000 description 3
- 125000005920 sec-butoxy group Chemical group 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 229940095064 tartrate Drugs 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- YJJOYDXULMKYLC-UHFFFAOYSA-N 1-(2,3-difluorophenyl)-2,2,2-trifluoroethanone Chemical compound FC1=CC=CC(C(=O)C(F)(F)F)=C1F YJJOYDXULMKYLC-UHFFFAOYSA-N 0.000 description 2
- BNUIDUFIVOSNQO-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidine-1-carbonyl)pyrrolidine-2,5-dione Chemical compound O=C1CCC(=O)N1C(=O)N1C(=O)CCC1=O BNUIDUFIVOSNQO-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- JWOHBPPVVDQMKB-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(C(O)=O)CC1 JWOHBPPVVDQMKB-UHFFFAOYSA-N 0.000 description 2
- 125000006082 1-ethyl-2-methyl-2-propenyl group Chemical group 0.000 description 2
- 125000006039 1-hexenyl group Chemical group 0.000 description 2
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 2
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical group C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 2
- 125000006040 2-hexenyl group Chemical group 0.000 description 2
- 125000006045 2-methyl-1-pentenyl group Chemical group 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- HVARAQWHPMCNGL-UHFFFAOYSA-N 3-(methoxymethyl)-2h-indazole Chemical compound C1=CC=C2C(COC)=NNC2=C1 HVARAQWHPMCNGL-UHFFFAOYSA-N 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 2
- GYLMCBOAXJVARF-UHFFFAOYSA-N 3-azabicyclo[2.2.1]heptane Chemical compound C1C2CCC1NC2 GYLMCBOAXJVARF-UHFFFAOYSA-N 0.000 description 2
- KPUSZZFAYGWAHZ-UHFFFAOYSA-N 3-azabicyclo[2.2.2]octane Chemical compound C1CC2CCC1NC2 KPUSZZFAYGWAHZ-UHFFFAOYSA-N 0.000 description 2
- PWVHZVWNAGLZFH-UHFFFAOYSA-N 3-azabicyclo[3.1.1]heptane Chemical compound C1C2CC1CNC2 PWVHZVWNAGLZFH-UHFFFAOYSA-N 0.000 description 2
- NEOIOGUWEUTYIH-UHFFFAOYSA-N 3-azabicyclo[3.2.0]heptane Chemical compound C1NCC2CCC21 NEOIOGUWEUTYIH-UHFFFAOYSA-N 0.000 description 2
- DCDAOVIVXGHHHU-UHFFFAOYSA-N 3-benzyl-3-azabicyclo[3.2.1]octan-8-one Chemical compound O=C1C(C2)CCC1CN2CC1=CC=CC=C1 DCDAOVIVXGHHHU-UHFFFAOYSA-N 0.000 description 2
- QLHYVFSGYNVMPW-UHFFFAOYSA-N 3-chloro-n-methylpropan-1-amine Chemical compound CNCCCCl QLHYVFSGYNVMPW-UHFFFAOYSA-N 0.000 description 2
- 125000006041 3-hexenyl group Chemical group 0.000 description 2
- HJBLUNHMOKFZQX-UHFFFAOYSA-N 3-hydroxy-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)N=NC2=C1 HJBLUNHMOKFZQX-UHFFFAOYSA-N 0.000 description 2
- DLYVQGSXLYYYLJ-UHFFFAOYSA-N 3-propan-2-yl-2h-indazole Chemical compound C1=CC=C2C(C(C)C)=NNC2=C1 DLYVQGSXLYYYLJ-UHFFFAOYSA-N 0.000 description 2
- ABBGCGQXFIEFAR-UHFFFAOYSA-N 3-propan-2-ylindazole-1-carboximidamide Chemical compound C1=CC=C2C(C(C)C)=NN(C(N)=N)C2=C1 ABBGCGQXFIEFAR-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- 125000006042 4-hexenyl group Chemical group 0.000 description 2
- 125000006058 4-methyl-4-pentenyl group Chemical group 0.000 description 2
- 125000006043 5-hexenyl group Chemical group 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- DENNCEQUAZKJGC-UHFFFAOYSA-N 6-azabicyclo[3.1.1]heptane Chemical compound C1CCC2CC1N2 DENNCEQUAZKJGC-UHFFFAOYSA-N 0.000 description 2
- DFOSXJTYCNLCKG-UHFFFAOYSA-N 7-fluoro-2h-indazole-3-carboxylic acid Chemical compound FC1=CC=CC2=C(C(=O)O)NN=C21 DFOSXJTYCNLCKG-UHFFFAOYSA-N 0.000 description 2
- IXFHNSOYCHUHQN-UHFFFAOYSA-N 7-fluoro-n-methoxy-n-methyl-2h-indazole-3-carboxamide Chemical compound C1=CC=C2C(C(=O)N(C)OC)=NNC2=C1F IXFHNSOYCHUHQN-UHFFFAOYSA-N 0.000 description 2
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 208000015163 Biliary Tract disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010051153 Diabetic gastroparesis Diseases 0.000 description 2
- 206010051244 Dyschezia Diseases 0.000 description 2
- 206010053155 Epigastric discomfort Diseases 0.000 description 2
- 206010015137 Eructation Diseases 0.000 description 2
- 206010052105 Gastrointestinal hypomotility Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010021333 Ileus paralytic Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010029333 Neurosis Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 239000005703 Trimethylamine hydrochloride Substances 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- VEQXJKYTJKBTBB-UHFFFAOYSA-N [1-(2-trimethylsilylethoxymethyl)indazol-3-yl]methanol Chemical compound C1=CC=C2N(COCC[Si](C)(C)C)N=C(CO)C2=C1 VEQXJKYTJKBTBB-UHFFFAOYSA-N 0.000 description 2
- RUPUODDRZXSBAU-UHFFFAOYSA-N [[amino-(3-ethyl-6-fluoroindazol-1-yl)methylidene]amino] 3-oxocyclobutane-1-carboxylate Chemical compound C12=CC(F)=CC=C2C(CC)=NN1C(=N)NOC(=O)C1CC(=O)C1 RUPUODDRZXSBAU-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000005456 alcohol based solvent Substances 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- 208000027687 belching Diseases 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 208000024330 bloating Diseases 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000023652 chronic gastritis Diseases 0.000 description 2
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 2
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 2
- 229960005132 cisapride Drugs 0.000 description 2
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- AUQDITHEDVOTCU-UHFFFAOYSA-N cyclopropyl cyanide Chemical compound N#CC1CC1 AUQDITHEDVOTCU-UHFFFAOYSA-N 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 208000024829 digestive system symptom Diseases 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 208000028299 esophageal disease Diseases 0.000 description 2
- 239000003759 ester based solvent Substances 0.000 description 2
- 239000004210 ether based solvent Substances 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- UPWPDUACHOATKO-UHFFFAOYSA-K gallium trichloride Chemical compound Cl[Ga](Cl)Cl UPWPDUACHOATKO-UHFFFAOYSA-K 0.000 description 2
- 239000003540 gamma secretase inhibitor Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002650 habitual effect Effects 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 208000008384 ileus Diseases 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 2
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 2
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 2
- 229940001447 lactate Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- HHUNWJWOJPWLNK-UHFFFAOYSA-N methyl 2-methylpyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(C)=C1 HHUNWJWOJPWLNK-UHFFFAOYSA-N 0.000 description 2
- ILIKHLPMOCBIRX-UHFFFAOYSA-N methyl 7-fluoro-2h-indazole-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=NNC2=C1F ILIKHLPMOCBIRX-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- BQFOVIOSQDLVGH-UHFFFAOYSA-N methyl n-(3-chloropropyl)-n-methylcarbamate Chemical compound COC(=O)N(C)CCCCl BQFOVIOSQDLVGH-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- WWQPATSTAMCYFS-UHFFFAOYSA-N n,n-bis(methoxymethyl)-1-phenylmethanamine Chemical compound COCN(COC)CC1=CC=CC=C1 WWQPATSTAMCYFS-UHFFFAOYSA-N 0.000 description 2
- NXQGEDVQXVTCDA-UHFFFAOYSA-N n,n-dimethyl-3-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]propan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCCN(C)C)=CC=CC2=C1 NXQGEDVQXVTCDA-UHFFFAOYSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 208000015238 neurotic disease Diseases 0.000 description 2
- 150000002826 nitrites Chemical class 0.000 description 2
- 125000006501 nitrophenyl group Chemical group 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229960003540 oxyquinoline Drugs 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 201000007620 paralytic ileus Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 208000000689 peptic esophagitis Diseases 0.000 description 2
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229960005235 piperonyl butoxide Drugs 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 201000007847 postgastrectomy syndrome Diseases 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- SCHKZZSVELPJKU-UHFFFAOYSA-N prx-03140 Chemical compound O=C1N(C(C)C)C=2SC=CC=2C(O)=C1C(=O)NCCCN1CCCCC1 SCHKZZSVELPJKU-UHFFFAOYSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- JAEIBKXSIXOLOL-UHFFFAOYSA-N pyrrolidin-1-ium-3-carboxylate Chemical compound OC(=O)C1CCNC1 JAEIBKXSIXOLOL-UHFFFAOYSA-N 0.000 description 2
- 229940076788 pyruvate Drugs 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 description 2
- 125000005930 sec-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- MXCAGVCUIHYAGH-UHFFFAOYSA-N tert-butyl 3,3-dimethyl-4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)C(C)(C)C1 MXCAGVCUIHYAGH-UHFFFAOYSA-N 0.000 description 2
- WPHYDBXMMSEFTR-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound C1C(CO)CC2CCC1N2C(=O)OC(C)(C)C WPHYDBXMMSEFTR-UHFFFAOYSA-N 0.000 description 2
- ZYNYREKPRWPYDC-UHFFFAOYSA-N tert-butyl 3-methylidene-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound C1C(=C)CC2CCC1N2C(=O)OC(C)(C)C ZYNYREKPRWPYDC-UHFFFAOYSA-N 0.000 description 2
- KXCSVEXHGFBUSQ-UHFFFAOYSA-N tert-butyl 4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-4-methylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(C)N1CCC2(OCCO2)CC1 KXCSVEXHGFBUSQ-UHFFFAOYSA-N 0.000 description 2
- IONMNRHLZXJDJX-UHFFFAOYSA-N tert-butyl 4-(2-iodoethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CCI)CC1 IONMNRHLZXJDJX-UHFFFAOYSA-N 0.000 description 2
- DZNPFTTUPBCMQM-UHFFFAOYSA-N tert-butyl 4-[5-(3-propan-2-ylindazol-1-yl)-1,2-oxazol-3-yl]piperidine-1-carboxylate Chemical compound C12=CC=CC=C2C(C(C)C)=NN1C(ON=1)=CC=1C1CCN(C(=O)OC(C)(C)C)CC1 DZNPFTTUPBCMQM-UHFFFAOYSA-N 0.000 description 2
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 2
- RGIQXIQVDYOOJQ-UHFFFAOYSA-N tert-butyl n-(2-fluoro-3-methoxyphenyl)carbamate Chemical compound COC1=CC=CC(NC(=O)OC(C)(C)C)=C1F RGIQXIQVDYOOJQ-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- SZYJELPVAFJOGJ-UHFFFAOYSA-N trimethylamine hydrochloride Chemical compound Cl.CN(C)C SZYJELPVAFJOGJ-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 208000014001 urinary system disease Diseases 0.000 description 2
- 201000002327 urinary tract obstruction Diseases 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- HKXICUDOIXLKLJ-PBINXNQUSA-N (1r,5s)-8-[(2-methylpropan-2-yl)oxycarbonyl]-8-azabicyclo[3.2.1]octane-3-carboxylic acid Chemical compound C1C(C(O)=O)C[C@H]2CC[C@@H]1N2C(=O)OC(C)(C)C HKXICUDOIXLKLJ-PBINXNQUSA-N 0.000 description 1
- HMOJKUDFFLOQTN-UHFFFAOYSA-N (2-aminophenyl)-cyclopropylmethanone Chemical compound NC1=CC=CC=C1C(=O)C1CC1 HMOJKUDFFLOQTN-UHFFFAOYSA-N 0.000 description 1
- XUJHKPSBHDQIOD-UHFFFAOYSA-N (2-bromo-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl)methanesulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)C(Br)C1C2(C)C XUJHKPSBHDQIOD-UHFFFAOYSA-N 0.000 description 1
- XBHPFCIWRHJDCP-UHFFFAOYSA-N (2-trimethylsilylphenyl) trifluoromethanesulfonate Chemical compound C[Si](C)(C)C1=CC=CC=C1OS(=O)(=O)C(F)(F)F XBHPFCIWRHJDCP-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- YMYLGVIBUGDMLT-QMMMGPOBSA-N (2s)-2-(phenylmethoxyamino)propanoic acid Chemical compound OC(=O)[C@H](C)NOCC1=CC=CC=C1 YMYLGVIBUGDMLT-QMMMGPOBSA-N 0.000 description 1
- XODSHWXKSMPDRP-LJQANCHMSA-N (4r)-4-cyclopropyl-7,8-difluoro-5-[4-(trifluoromethyl)phenyl]sulfonyl-1,4-dihydropyrazolo[4,3-c]quinoline Chemical compound C1([C@H]2N(C=3C=C(C(=CC=3C=3NN=CC=32)F)F)S(=O)(=O)C=2C=CC(=CC=2)C(F)(F)F)CC1 XODSHWXKSMPDRP-LJQANCHMSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000004893 1,1-dimethylethylamino group Chemical group CC(C)(C)N* 0.000 description 1
- ADKDJHASTPQGEO-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrole Chemical compound C1CNC2CCCC21 ADKDJHASTPQGEO-UHFFFAOYSA-N 0.000 description 1
- UZHVXJZEHGSWQV-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole Chemical compound C1NCC2CCCC21 UZHVXJZEHGSWQV-UHFFFAOYSA-N 0.000 description 1
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 description 1
- POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical compound N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 description 1
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- KPKNTUUIEVXMOH-UHFFFAOYSA-N 1,4-dioxa-8-azaspiro[4.5]decane Chemical compound O1CCOC11CCNCC1 KPKNTUUIEVXMOH-UHFFFAOYSA-N 0.000 description 1
- FEQOLYDPQKHFTD-UHFFFAOYSA-N 1-(2,2-diphenyloxolan-3-yl)-n,n-dimethylmethanamine;hydrochloride Chemical compound Cl.CN(C)CC1CCOC1(C=1C=CC=CC=1)C1=CC=CC=C1 FEQOLYDPQKHFTD-UHFFFAOYSA-N 0.000 description 1
- FWGUMEVCNXPUBD-UHFFFAOYSA-N 1-(2,3-difluorophenyl)-2,2,2-trifluoroethanol Chemical compound FC(F)(F)C(O)C1=CC=CC(F)=C1F FWGUMEVCNXPUBD-UHFFFAOYSA-N 0.000 description 1
- ZBORFQJDYSRFBH-UHFFFAOYSA-N 1-(2-aminophenyl)-2-methylpropan-1-one Chemical compound CC(C)C(=O)C1=CC=CC=C1N ZBORFQJDYSRFBH-UHFFFAOYSA-N 0.000 description 1
- DSMVXRSJGPYOOA-UHFFFAOYSA-N 1-(7-fluoro-2h-indazol-3-yl)ethanone Chemical compound C1=CC=C2C(C(=O)C)=NNC2=C1F DSMVXRSJGPYOOA-UHFFFAOYSA-N 0.000 description 1
- MBHLLEMPOJORAC-DLBZAZTESA-N 1-[(2r)-2-[[(3s)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]pyrrolidin-1-yl]-2-hydroxyethanone Chemical compound C([C@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)C(C)C)CN1C[C@H]1CCCN1C(=O)CO MBHLLEMPOJORAC-DLBZAZTESA-N 0.000 description 1
- QIDVQLREYCHXBT-QGZVFWFLSA-N 1-[(2r)-2-[[4-[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]pyrrolidin-1-yl]-2-hydroxyethanone Chemical compound C12=C(F)C=CC=C2C(C(C)C)=NN1C(N=1)=NOC=1C(CC1)CCN1C[C@H]1CCCN1C(=O)CO QIDVQLREYCHXBT-QGZVFWFLSA-N 0.000 description 1
- MBHLLEMPOJORAC-IRXDYDNUSA-N 1-[(2s)-2-[[(3s)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]pyrrolidin-1-yl]-2-hydroxyethanone Chemical compound C([C@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)C(C)C)CN1C[C@@H]1CCCN1C(=O)CO MBHLLEMPOJORAC-IRXDYDNUSA-N 0.000 description 1
- DRTQHJPVMGBUCF-UCVXFZOQSA-N 1-[(2s,3s,4s,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 1
- CUDONWZUXRTGLR-IAGOWNOFSA-N 1-[(3r)-3-[[(3r)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]pyrrolidin-1-yl]-2-hydroxyethanone Chemical compound C([C@@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)C(C)C)CN1C[C@H]1CCN(C(=O)CO)C1 CUDONWZUXRTGLR-IAGOWNOFSA-N 0.000 description 1
- HGZOAZODDJVYTO-QZTJIDSGSA-N 1-[(3r)-3-[[(3r)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]pyrrolidin-1-yl]-2-methoxyethanone Chemical compound C1N(C(=O)COC)CC[C@@H]1CN1C[C@@H](CC=2ON=C(N=2)N2C3=C(F)C=CC=C3C(C(C)C)=N2)CC1 HGZOAZODDJVYTO-QZTJIDSGSA-N 0.000 description 1
- CUDONWZUXRTGLR-DLBZAZTESA-N 1-[(3r)-3-[[(3s)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]pyrrolidin-1-yl]-2-hydroxyethanone Chemical compound C([C@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)C(C)C)CN1C[C@H]1CCN(C(=O)CO)C1 CUDONWZUXRTGLR-DLBZAZTESA-N 0.000 description 1
- OEQYNZXSMQIWST-MRXNPFEDSA-N 1-[(3r)-3-[[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]pyrrolidin-1-yl]-2-methoxyethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C[C@H]1CCN(C(=O)COC)C1 OEQYNZXSMQIWST-MRXNPFEDSA-N 0.000 description 1
- KSHNUMSXRLBXDI-MRXNPFEDSA-N 1-[(3r)-3-[[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]pyrrolidin-1-yl]ethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C[C@H]1CCN(C(C)=O)C1 KSHNUMSXRLBXDI-MRXNPFEDSA-N 0.000 description 1
- HGZOAZODDJVYTO-MSOLQXFVSA-N 1-[(3s)-3-[[(3r)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]pyrrolidin-1-yl]-2-methoxyethanone Chemical compound C1N(C(=O)COC)CC[C@H]1CN1C[C@@H](CC=2ON=C(N=2)N2C3=C(F)C=CC=C3C(C(C)C)=N2)CC1 HGZOAZODDJVYTO-MSOLQXFVSA-N 0.000 description 1
- NWJMYBCZZZLUFH-MSOLQXFVSA-N 1-[(3s)-3-[[(3r)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]pyrrolidin-1-yl]ethanone Chemical compound C([C@@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)C(C)C)CN1C[C@@H]1CCN(C(C)=O)C1 NWJMYBCZZZLUFH-MSOLQXFVSA-N 0.000 description 1
- CUDONWZUXRTGLR-IRXDYDNUSA-N 1-[(3s)-3-[[(3s)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]pyrrolidin-1-yl]-2-hydroxyethanone Chemical compound C([C@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)C(C)C)CN1C[C@@H]1CCN(C(=O)CO)C1 CUDONWZUXRTGLR-IRXDYDNUSA-N 0.000 description 1
- DBPUJDHYTDWYKN-HNNXBMFYSA-N 1-[(3s)-3-[[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]pyrrolidin-1-yl]-2-hydroxyethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C[C@@H]1CCN(C(=O)CO)C1 DBPUJDHYTDWYKN-HNNXBMFYSA-N 0.000 description 1
- VTUNMJQOMOJPED-UHFFFAOYSA-N 1-[3,3-dimethyl-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]piperidine-4-carboxylic acid Chemical compound CC1(C)CN(C(=O)OC(C)(C)C)CCC1N1CCC(C(O)=O)CC1 VTUNMJQOMOJPED-UHFFFAOYSA-N 0.000 description 1
- RLUCYBFCLXANSO-BTJKTKAUSA-N 1-[3-[2-(1-benzothiophen-5-yl)ethoxy]propyl]azetidin-3-ol;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C1C(O)CN1CCCOCCC1=CC=C(SC=C2)C2=C1 RLUCYBFCLXANSO-BTJKTKAUSA-N 0.000 description 1
- RLZYHVVQPIAASE-MRXNPFEDSA-N 1-[3-[[(3r)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]azetidin-1-yl]-2-methoxyethanone Chemical compound C1N(C(=O)COC)CC1CN1C[C@@H](CC=2ON=C(N=2)N2C3=C(F)C=CC=C3C(C(C)C)=N2)CC1 RLZYHVVQPIAASE-MRXNPFEDSA-N 0.000 description 1
- RLZYHVVQPIAASE-INIZCTEOSA-N 1-[3-[[(3s)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]azetidin-1-yl]-2-methoxyethanone Chemical compound C1N(C(=O)COC)CC1CN1C[C@H](CC=2ON=C(N=2)N2C3=C(F)C=CC=C3C(C(C)C)=N2)CC1 RLZYHVVQPIAASE-INIZCTEOSA-N 0.000 description 1
- BAJCMSHWHVWULL-UHFFFAOYSA-N 1-[3-[[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]azetidin-1-yl]-2-hydroxyethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1CC1CN(C(=O)CO)C1 BAJCMSHWHVWULL-UHFFFAOYSA-N 0.000 description 1
- BQPBKRHIEZFMSQ-UHFFFAOYSA-N 1-[3-[[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]azetidin-1-yl]-2-methoxyethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1CC1CN(C(=O)COC)C1 BQPBKRHIEZFMSQ-UHFFFAOYSA-N 0.000 description 1
- ZWYWLDXUNIOMHJ-UHFFFAOYSA-N 1-[3-[[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]azetidin-1-yl]ethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1CC1CN(C(C)=O)C1 ZWYWLDXUNIOMHJ-UHFFFAOYSA-N 0.000 description 1
- JXNJLEXUJPZADT-UHFFFAOYSA-N 1-[3-[[4-[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]azetidin-1-yl]ethanone Chemical compound C12=C(F)C=CC=C2C(C(C)C)=NN1C(N=1)=NOC=1C(CC1)CCN1CC1CN(C(C)=O)C1 JXNJLEXUJPZADT-UHFFFAOYSA-N 0.000 description 1
- LIYLTQQDABRNRX-UHFFFAOYSA-N 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid Chemical compound C=1C=C(C=2C=C(Cl)C(Cl)=CC=2)C(F)=CC=1C1(C(=O)O)CC1 LIYLTQQDABRNRX-UHFFFAOYSA-N 0.000 description 1
- OOYQGQXAIOWLDW-QGZVFWFLSA-N 1-[4-[(3r)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]piperidin-1-yl]-2-methoxyethanone Chemical compound C1CN(C(=O)COC)CCC1N1C[C@@H](CC=2ON=C(N=2)N2C3=C(F)C=CC=C3C(C(C)C)=N2)CC1 OOYQGQXAIOWLDW-QGZVFWFLSA-N 0.000 description 1
- QWAPFRNMUGMNHY-UHFFFAOYSA-N 1-[4-[4-[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]piperidin-1-yl]ethanone Chemical compound C12=C(F)C=CC=C2C(C(C)C)=NN1C(N=1)=NOC=1C(CC1)CCN1C1CCN(C(C)=O)CC1 QWAPFRNMUGMNHY-UHFFFAOYSA-N 0.000 description 1
- KSRNURQSWQDXOM-UHFFFAOYSA-N 1-[4-[[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]piperidin-1-yl]-2-hydroxyethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1CC1CCN(C(=O)CO)CC1 KSRNURQSWQDXOM-UHFFFAOYSA-N 0.000 description 1
- ZBTRNKJUAQYEMJ-UHFFFAOYSA-N 1-[4-methyl-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]piperidine-4-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(C)N1CCC(C(O)=O)CC1 ZBTRNKJUAQYEMJ-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- MYHJCTUTPIKNAT-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl piperidine-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CC1 MYHJCTUTPIKNAT-UHFFFAOYSA-N 0.000 description 1
- MVHJLPVFTFKCGA-UHFFFAOYSA-N 1-o-tert-butyl 4-o-methyl 2-methylpiperidine-1,4-dicarboxylate Chemical compound COC(=O)C1CCN(C(=O)OC(C)(C)C)C(C)C1 MVHJLPVFTFKCGA-UHFFFAOYSA-N 0.000 description 1
- KRGNRMHCPSNYBM-UHFFFAOYSA-N 1-propan-2-ylindazole hydrochloride Chemical compound Cl.CC(C)n1ncc2ccccc12 KRGNRMHCPSNYBM-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- KWTCVAHCQGKXAZ-UHFFFAOYSA-N 1H-indazole-3-carboxylic acid methyl ester Chemical compound C1=CC=C2C(C(=O)OC)=NNC2=C1 KWTCVAHCQGKXAZ-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
- WDBAXYQUOZDFOJ-UHFFFAOYSA-N 2,3-difluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1F WDBAXYQUOZDFOJ-UHFFFAOYSA-N 0.000 description 1
- GKPHNZYMLJPYJJ-UHFFFAOYSA-N 2,3-difluorobenzonitrile Chemical group FC1=CC=CC(C#N)=C1F GKPHNZYMLJPYJJ-UHFFFAOYSA-N 0.000 description 1
- DZMNAVXYIHONJI-UHFFFAOYSA-N 2-(3-chloroindazol-1-yl)-5-piperidin-4-yl-1,3,4-oxadiazole;hydrochloride Chemical compound Cl.C12=CC=CC=C2C(Cl)=NN1C(O1)=NN=C1C1CCNCC1 DZMNAVXYIHONJI-UHFFFAOYSA-N 0.000 description 1
- YBAWYTYNMZWMMJ-UHFFFAOYSA-N 2-(6-fluoro-1h-indol-3-yl)-n-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]ethanamine Chemical compound FC(F)C(F)(F)COC1=CC=CC(CNCCC=2C3=CC=C(F)C=C3NC=2)=C1 YBAWYTYNMZWMMJ-UHFFFAOYSA-N 0.000 description 1
- FRAPXMGYAOBWMD-UHFFFAOYSA-N 2-(7-fluoro-2h-indazol-3-yl)propan-2-ol Chemical compound C1=CC=C2C(C(C)(O)C)=NNC2=C1F FRAPXMGYAOBWMD-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- XJBHWDKRZXYEDL-UHFFFAOYSA-N 2-(oxan-2-yl)ethanol Chemical compound OCCC1CCCCO1 XJBHWDKRZXYEDL-UHFFFAOYSA-N 0.000 description 1
- ARLMEMATTRYURD-UHFFFAOYSA-N 2-(oxan-2-yl)ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCC1OCCCC1 ARLMEMATTRYURD-UHFFFAOYSA-N 0.000 description 1
- VUQWWGUPJYDAOH-UHFFFAOYSA-N 2-(oxolan-2-yl)ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCC1OCCC1 VUQWWGUPJYDAOH-UHFFFAOYSA-N 0.000 description 1
- GNIRITULTPTAQW-KNQAVFIVSA-N 2-[4-[4-[(3ar,6ar)-5-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-1-yl]phenyl]phenyl]pyridazin-3-one Chemical compound C([C@@H]1CN(C[C@@H]11)C)CN1C(C=C1)=CC=C1C(C=C1)=CC=C1N1N=CC=CC1=O GNIRITULTPTAQW-KNQAVFIVSA-N 0.000 description 1
- UBSGPYKIMLIGPC-UHFFFAOYSA-N 2-[[3-(methoxymethyl)indazol-1-yl]methoxy]ethyl-trimethylsilane Chemical compound C1=CC=C2C(COC)=NN(COCC[Si](C)(C)C)C2=C1 UBSGPYKIMLIGPC-UHFFFAOYSA-N 0.000 description 1
- IZQAUUVBKYXMET-UHFFFAOYSA-N 2-bromoethanamine Chemical group NCCBr IZQAUUVBKYXMET-UHFFFAOYSA-N 0.000 description 1
- MFQMAJVFQXQMBG-UHFFFAOYSA-N 2-fluoro-3-methoxyaniline;hydrochloride Chemical compound Cl.COC1=CC=CC(N)=C1F MFQMAJVFQXQMBG-UHFFFAOYSA-N 0.000 description 1
- AOLCMZUHHVCZER-UHFFFAOYSA-N 2-fluoro-5-methoxyaniline;hydrochloride Chemical compound Cl.COC1=CC=C(F)C(N)=C1 AOLCMZUHHVCZER-UHFFFAOYSA-N 0.000 description 1
- 125000004791 2-fluoroethoxy group Chemical group FCCO* 0.000 description 1
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 1
- JYCRXMSJGZWACP-UHFFFAOYSA-N 2-methyl-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound CC1CC(C(O)=O)CCN1C(=O)OC(C)(C)C JYCRXMSJGZWACP-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- WPHUUIODWRNJLO-UHFFFAOYSA-N 2-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1S(Cl)(=O)=O WPHUUIODWRNJLO-UHFFFAOYSA-N 0.000 description 1
- RECARUFTCUAFPV-UHFFFAOYSA-N 2-oxa-7-azaspiro[3.5]nonane Chemical compound C1OCC11CCNCC1 RECARUFTCUAFPV-UHFFFAOYSA-N 0.000 description 1
- OXXXNXISRXFPBK-UHFFFAOYSA-N 2-oxa-8-azaspiro[4.5]decane Chemical compound C1OCCC21CCNCC2 OXXXNXISRXFPBK-UHFFFAOYSA-N 0.000 description 1
- GRRJLVAHCMYTEP-UHFFFAOYSA-N 2h-pyridine-1-carbonitrile Chemical compound N#CN1CC=CC=C1 GRRJLVAHCMYTEP-UHFFFAOYSA-N 0.000 description 1
- WUCNXNGEHMFXNQ-UHFFFAOYSA-N 2h-pyridine-1-carboximidamide Chemical compound NC(=N)N1CC=CC=C1 WUCNXNGEHMFXNQ-UHFFFAOYSA-N 0.000 description 1
- LSSGAMFKGPXTSG-UHFFFAOYSA-N 3-(3-cyclobutylindazol-1-yl)-5-[1-(2-methylpropyl)piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C1CN(CC(C)C)CCC1C1=NC(N2C3=CC=CC=C3C(C3CCC3)=N2)=NO1 LSSGAMFKGPXTSG-UHFFFAOYSA-N 0.000 description 1
- SIUIIWXMVCWPFU-UHFFFAOYSA-N 3-(3-ethyl-6-fluoroindazol-1-yl)-5-[1-(oxolan-3-yl)piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=CC(F)=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C1CCOC1 SIUIIWXMVCWPFU-UHFFFAOYSA-N 0.000 description 1
- QDGPBSMDNXXFIY-UHFFFAOYSA-N 3-(3-ethylindazol-1-yl)-5-[1-(3-methoxypropyl)piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=CC=CC=C2C(CC)=NN1C(N=1)=NOC=1C1CCN(CCCOC)CC1 QDGPBSMDNXXFIY-UHFFFAOYSA-N 0.000 description 1
- KETQPYPHCGIIQR-UHFFFAOYSA-N 3-(difluoromethyl)-2h-indazole Chemical compound C1=CC=C2C(C(F)F)=NNC2=C1 KETQPYPHCGIIQR-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- BXKYFUGAAFLYJL-BXGYHSFXSA-N 3-[(5e)-5-[(2,4-dimethoxyphenyl)methylidene]-3,4-dihydro-2h-pyridin-6-yl]pyridine;dihydrochloride Chemical compound Cl.Cl.COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 BXKYFUGAAFLYJL-BXGYHSFXSA-N 0.000 description 1
- JNIGXKDHKITRAV-UHFFFAOYSA-N 3-[3-(3-ethyl-6-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]cyclobutan-1-one Chemical compound C12=CC(F)=CC=C2C(CC)=NN1C(N=1)=NOC=1C1CC(=O)C1 JNIGXKDHKITRAV-UHFFFAOYSA-N 0.000 description 1
- RVBGJIWRUYUXGK-UHFFFAOYSA-N 3-[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]cyclobutan-1-one Chemical compound C12=C(F)C=CC=C2C(C(C)C)=NN1C(N=1)=NOC=1C1CC(=O)C1 RVBGJIWRUYUXGK-UHFFFAOYSA-N 0.000 description 1
- XCGJIFAKUZNNOR-UHFFFAOYSA-N 3-[4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexyl]propanoic acid Chemical compound C1CC(CCC(=O)O)CCC1(S(=O)(=O)C=1C=CC(Cl)=CC=1)C1=CC(F)=CC=C1F XCGJIFAKUZNNOR-UHFFFAOYSA-N 0.000 description 1
- BWNJKRFSQWSCLZ-UHFFFAOYSA-N 3-[4-[3-(3-ethylindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]propan-1-ol Chemical compound C12=CC=CC=C2C(CC)=NN1C(N=1)=NOC=1C1CCN(CCCO)CC1 BWNJKRFSQWSCLZ-UHFFFAOYSA-N 0.000 description 1
- NRZRFNYKMSAZBI-ZETCQYMHSA-N 3-[[(2s)-2-amino-3-methylbutanoyl]amino]propane-1-sulfonic acid Chemical compound CC(C)[C@H](N)C(=O)NCCCS(O)(=O)=O NRZRFNYKMSAZBI-ZETCQYMHSA-N 0.000 description 1
- QPHAGNNWDZSKJH-UHFFFAOYSA-N 3-chloro-2h-indazole Chemical compound C1=CC=CC2=C(Cl)NN=C21 QPHAGNNWDZSKJH-UHFFFAOYSA-N 0.000 description 1
- TVAMARSGRKHWKO-UHFFFAOYSA-N 3-chloroindazole-1-carbonitrile Chemical compound C1=CC=C2C(Cl)=NN(C#N)C2=C1 TVAMARSGRKHWKO-UHFFFAOYSA-N 0.000 description 1
- JAVBTLDJPYBQEW-UHFFFAOYSA-N 3-cyclopropyl-2h-indazole Chemical compound C1CC1C1=NNC2=CC=CC=C12 JAVBTLDJPYBQEW-UHFFFAOYSA-N 0.000 description 1
- RWKBUEHYMDJSOE-UHFFFAOYSA-N 3-ethyl-7-fluoro-2h-indazole Chemical compound FC1=CC=CC2=C(CC)NN=C21 RWKBUEHYMDJSOE-UHFFFAOYSA-N 0.000 description 1
- WWXALVAXURMRNT-UHFFFAOYSA-N 3-ethyl-n'-hydroxyindazole-1-carboximidamide Chemical group C1=CC=C2C(CC)=NN(C(N)=NO)C2=C1 WWXALVAXURMRNT-UHFFFAOYSA-N 0.000 description 1
- IENOFRJPUPTEMI-UHFFFAOYSA-N 3-oxocyclobutane-1-carboxylic acid Chemical compound OC(=O)C1CC(=O)C1 IENOFRJPUPTEMI-UHFFFAOYSA-N 0.000 description 1
- PRZULIMQZFBGQP-UHFFFAOYSA-N 4-[3-(3-ethylindazol-1-yl)-1,2,4-oxadiazol-5-yl]cyclohexan-1-one Chemical compound C12=CC=CC=C2C(CC)=NN1C(N=1)=NOC=1C1CCC(=O)CC1 PRZULIMQZFBGQP-UHFFFAOYSA-N 0.000 description 1
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 1
- JSRMPTJZAJUPGZ-UHFFFAOYSA-N 4-fluoro-3-nitrophenol Chemical compound OC1=CC=C(F)C([N+]([O-])=O)=C1 JSRMPTJZAJUPGZ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- MBCTVLATHCCVRG-UHFFFAOYSA-N 4-methoxycarbonyl-2-methylpiperidine-1-carboxylic acid Chemical compound COC(=O)C1CCN(C(C)C1)C(O)=O MBCTVLATHCCVRG-UHFFFAOYSA-N 0.000 description 1
- OWLXUYGCLDGHJJ-UHFFFAOYSA-N 4-oxocyclohexanecarboxylic acid Chemical group OC(=O)C1CCC(=O)CC1 OWLXUYGCLDGHJJ-UHFFFAOYSA-N 0.000 description 1
- 108091005435 5-HT6 receptors Proteins 0.000 description 1
- ZSFAZNJBEGJGAS-UHFFFAOYSA-N 5-[1-(3-methoxypropyl)piperidin-4-yl]-3-(3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazole Chemical compound C1CN(CCCOC)CCC1C1=NC(N2C3=CC=CC=C3C(C(C)C)=N2)=NO1 ZSFAZNJBEGJGAS-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- DWMXPIRFMDAZEI-UHFFFAOYSA-N 5-piperidin-4-yl-3-(6-propan-2-ylpyrrolo[2,3-b]pyridin-1-yl)-1,2,4-oxadiazole;hydrochloride Chemical compound Cl.C12=NC(C(C)C)=CC=C2C=CN1C(N=1)=NOC=1C1CCNCC1 DWMXPIRFMDAZEI-UHFFFAOYSA-N 0.000 description 1
- ODRWCQWAJNXMHA-UHFFFAOYSA-N 5-piperidin-4-yl-3-pyrrolo[2,3-b]pyridin-1-yl-1,2,4-oxadiazole;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1CNCCC1C1=NC(N2C3=NC=CC=C3C=C2)=NO1 ODRWCQWAJNXMHA-UHFFFAOYSA-N 0.000 description 1
- RDXWDCPAZPRWIY-UHFFFAOYSA-N 6-propan-2-yl-1h-pyrrolo[2,3-b]pyridine Chemical compound CC(C)C1=CC=C2C=CNC2=N1 RDXWDCPAZPRWIY-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- DPJXVBDDFSOEML-UHFFFAOYSA-N 7-chloro-3-ethyl-2h-indazole Chemical compound ClC1=CC=CC2=C(CC)NN=C21 DPJXVBDDFSOEML-UHFFFAOYSA-N 0.000 description 1
- FQNFMARSNKXCAF-UHFFFAOYSA-N 7-fluoro-1h-indazole Chemical compound FC1=CC=CC2=C1NN=C2 FQNFMARSNKXCAF-UHFFFAOYSA-N 0.000 description 1
- ORVBQAOXGAHTJZ-UHFFFAOYSA-N 7-fluoro-3-(trifluoromethyl)-2h-indazole Chemical compound FC1=CC=CC2=C1NN=C2C(F)(F)F ORVBQAOXGAHTJZ-UHFFFAOYSA-N 0.000 description 1
- NZLJQLITHWOQBC-UHFFFAOYSA-N 7-fluoro-3-iodo-2h-indazole Chemical compound FC1=CC=CC2=C1NN=C2I NZLJQLITHWOQBC-UHFFFAOYSA-N 0.000 description 1
- JSNXZSNNWRSEII-UHFFFAOYSA-N 7-fluoro-3-prop-1-en-2-yl-1h-indazole Chemical compound C1=CC=C2C(C(=C)C)=NNC2=C1F JSNXZSNNWRSEII-UHFFFAOYSA-N 0.000 description 1
- KRRSQJOVDWYKHH-UHFFFAOYSA-N 7-fluoro-5-methyl-3-[1-(oxan-4-yl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC(C)=CC(F)=C2NC(=O)N1C(CC1)CCN1C1CCOCC1 KRRSQJOVDWYKHH-UHFFFAOYSA-N 0.000 description 1
- VFPMCLQMAUVEHD-UCPSWNCLSA-N 7beta-hydroxyepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3[C@@H](O)C[C@H]21 VFPMCLQMAUVEHD-UCPSWNCLSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 239000000774 AMPA receptor agonist Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- XEAOPVUAMONVLA-QGZVFWFLSA-N Avagacestat Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](CCC(F)(F)F)C(=O)N)CC(C(=C1)F)=CC=C1C=1N=CON=1 XEAOPVUAMONVLA-QGZVFWFLSA-N 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 102100021257 Beta-secretase 1 Human genes 0.000 description 1
- RXTKNYRXUAOXRS-UHFFFAOYSA-N C(C)(C)(C)C12CNCC(CC1)C2=O Chemical compound C(C)(C)(C)C12CNCC(CC1)C2=O RXTKNYRXUAOXRS-UHFFFAOYSA-N 0.000 description 1
- SAHAZKDOYQREKX-UHFFFAOYSA-N C(C)(C)(C)C12CNCC(CCC1)C2=O Chemical compound C(C)(C)(C)C12CNCC(CCC1)C2=O SAHAZKDOYQREKX-UHFFFAOYSA-N 0.000 description 1
- CLVHDJBCZUEFBQ-KRWDZBQOSA-N CCc1nn(-c2noc(n2)C2CCN(C[C@@H]3CCCN3C)CC2)c2ccccc12 Chemical compound CCc1nn(-c2noc(n2)C2CCN(C[C@@H]3CCCN3C)CC2)c2ccccc12 CLVHDJBCZUEFBQ-KRWDZBQOSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- DSCFFEYYQKSRSV-KLJZZCKASA-N D-pinitol Chemical compound CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-KLJZZCKASA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- 239000002139 L01XE22 - Masitinib Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229940076380 PDE9 inhibitor Drugs 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940122777 Tau aggregation inhibitor Drugs 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- AZFNGPAYDKGCRB-XCPIVNJJSA-M [(1s,2s)-2-amino-1,2-diphenylethyl]-(4-methylphenyl)sulfonylazanide;chlororuthenium(1+);1-methyl-4-propan-2-ylbenzene Chemical compound [Ru+]Cl.CC(C)C1=CC=C(C)C=C1.C1=CC(C)=CC=C1S(=O)(=O)[N-][C@@H](C=1C=CC=CC=1)[C@@H](N)C1=CC=CC=C1 AZFNGPAYDKGCRB-XCPIVNJJSA-M 0.000 description 1
- GTUIQNHJSXQMKW-OCAPTIKFSA-N [(3aS,6aR)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl]-(5-chlorofuran-2-yl)methanone Chemical compound Clc1ccc(o1)C(=O)N1C[C@@H]2CNC[C@@H]2C1 GTUIQNHJSXQMKW-OCAPTIKFSA-N 0.000 description 1
- PBHFNBQPZCRWQP-AZUAARDMSA-N [(3aS,8bR)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate Chemical compound CN([C@H]1[C@](C2=C3)(C)CCN1C)C2=CC=C3OC(=O)NC1=CC=CC=C1 PBHFNBQPZCRWQP-AZUAARDMSA-N 0.000 description 1
- SPCMQFLNOVTUBM-UHFFFAOYSA-N [7-(dimethylazaniumyl)-10h-phenothiazin-3-yl]-dimethylazanium;methanesulfonate Chemical compound CS([O-])(=O)=O.CS([O-])(=O)=O.C1=C([NH+](C)C)C=C2SC3=CC([NH+](C)C)=CC=C3NC2=C1 SPCMQFLNOVTUBM-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- AKUNRPXJLWGUSM-UHFFFAOYSA-N acetonitrile;formamide Chemical compound CC#N.NC=O AKUNRPXJLWGUSM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 description 1
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- NETXMUIMUZJUTB-UHFFFAOYSA-N apabetalone Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 NETXMUIMUZJUTB-UHFFFAOYSA-N 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- GFZWHAAOIVMHOI-UHFFFAOYSA-N azetidine-3-carboxylic acid Chemical compound OC(=O)C1CNC1 GFZWHAAOIVMHOI-UHFFFAOYSA-N 0.000 description 1
- 229950001863 bapineuzumab Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- CSDHNKCWCCXZCS-UHFFFAOYSA-N boron;methylsulfanylmethane;oxolane Chemical compound [B].CSC.C1CCOC1 CSDHNKCWCCXZCS-UHFFFAOYSA-N 0.000 description 1
- VEWFZHAHZPVQES-UHFFFAOYSA-N boron;n,n-diethylethanamine Chemical compound [B].CCN(CC)CC VEWFZHAHZPVQES-UHFFFAOYSA-N 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 1
- OXKRFEWMSWPKKV-RXVVDRJESA-N bradanicline Chemical compound C([C@@H]1N2CCC(CC2)[C@@H]1NC(=O)C=1OC2=CC=CC=C2C=1)C1=CC=CN=C1 OXKRFEWMSWPKKV-RXVVDRJESA-N 0.000 description 1
- KXVUSQIDCZRUKF-UHFFFAOYSA-N bromocyclobutane Chemical compound BrC1CCC1 KXVUSQIDCZRUKF-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- SXMBKHYDZOCBMT-PPUGGXLSSA-N chembl2151197 Chemical compound C1[C@@H](C(=O)NCC)C[C@@]1(F)C(C=C1F)=CC=C1CN1CCCC1 SXMBKHYDZOCBMT-PPUGGXLSSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- UTMVACIBQLDZLP-UHFFFAOYSA-N crisdesalazine Chemical compound C1=C(O)C(C(=O)O)=CC(NCCC=2C=CC(=CC=2)C(F)(F)F)=C1 UTMVACIBQLDZLP-UHFFFAOYSA-N 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000002243 cyclohexanonyl group Chemical group *C1(*)C(=O)C(*)(*)C(*)(*)C(*)(*)C1(*)* 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexyloxide Natural products O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- BGTOWKSIORTVQH-HOSYLAQJSA-N cyclopentanone Chemical group O=[13C]1CCCC1 BGTOWKSIORTVQH-HOSYLAQJSA-N 0.000 description 1
- DWLTUUXCVGVRAV-XWRHUKJGSA-N davunetide Chemical compound N([C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O DWLTUUXCVGVRAV-XWRHUKJGSA-N 0.000 description 1
- 229950008614 davunetide Drugs 0.000 description 1
- 108010042566 davunetide Proteins 0.000 description 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 125000004915 dibutylamino group Chemical group C(CCC)N(CCCC)* 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical class CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- OPQRBXUBWHDHPQ-UHFFFAOYSA-N etazolate Chemical compound CCOC(=O)C1=CN=C2N(CC)N=CC2=C1NN=C(C)C OPQRBXUBWHDHPQ-UHFFFAOYSA-N 0.000 description 1
- 229950009329 etazolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- SNSYYBGUDOYAMB-UHFFFAOYSA-N ethyl 2-(oxolan-2-yl)acetate Chemical compound CCOC(=O)CC1CCCO1 SNSYYBGUDOYAMB-UHFFFAOYSA-N 0.000 description 1
- RLWYQPWCTNGHEF-UHFFFAOYSA-N ethyl 3-aminocyclobutane-1-carboxylate Chemical compound CCOC(=O)C1CC(N)C1 RLWYQPWCTNGHEF-UHFFFAOYSA-N 0.000 description 1
- RUJPPJYDHHAEEK-UHFFFAOYSA-N ethyl piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCNCC1 RUJPPJYDHHAEEK-UHFFFAOYSA-N 0.000 description 1
- KZGWPHUWNWRTEP-UHFFFAOYSA-N ethynyl-tri(propan-2-yl)silane Chemical group CC(C)[Si](C#C)(C(C)C)C(C)C KZGWPHUWNWRTEP-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 229940009600 gammagard Drugs 0.000 description 1
- 229950002508 gantenerumab Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- QOSATHPSBFQAML-UHFFFAOYSA-N hydrogen peroxide;hydrate Chemical compound O.OO QOSATHPSBFQAML-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 description 1
- 229960004655 masitinib Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- KNWQLFOXPQZGPX-UHFFFAOYSA-N methanesulfonyl fluoride Chemical compound CS(F)(=O)=O KNWQLFOXPQZGPX-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- UKCLLWHSIKYQLW-UHFFFAOYSA-N methyl 4-[3-[3-(3-ethylindazol-1-yl)-1,2,4-oxadiazol-5-yl]azetidin-1-yl]piperidine-1-carboxylate Chemical compound C12=CC=CC=C2C(CC)=NN1C(N=1)=NOC=1C(C1)CN1C1CCN(C(=O)OC)CC1 UKCLLWHSIKYQLW-UHFFFAOYSA-N 0.000 description 1
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- MWIHJVKBDBJMKH-UHFFFAOYSA-N methyl n-(2-bromoethyl)carbamate Chemical compound COC(=O)NCCBr MWIHJVKBDBJMKH-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
- JNMIXMFEVJHFNY-UHFFFAOYSA-M methyl(triphenyl)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 JNMIXMFEVJHFNY-UHFFFAOYSA-M 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 229960004085 mosapride Drugs 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- BTJXAAHGILJALK-UHFFFAOYSA-N n'-hydroxy-6-propan-2-ylpyrrolo[2,3-b]pyridine-1-carboximidamide Chemical compound CC(C)C1=CC=C2C=CN(C(=N)NO)C2=N1 BTJXAAHGILJALK-UHFFFAOYSA-N 0.000 description 1
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- NLBJMRFPAKOOSM-UHFFFAOYSA-N n-(2,2-dimethylpropylideneamino)-4-methylbenzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)NN=CC(C)(C)C)C=C1 NLBJMRFPAKOOSM-UHFFFAOYSA-N 0.000 description 1
- SSRDSYXGYPJKRR-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophene-2-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC(C=CC=C2Cl)=C2S1 SSRDSYXGYPJKRR-ZDUSSCGKSA-N 0.000 description 1
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
- OGZQTTHDGQBLBT-UHFFFAOYSA-N neramexane Chemical compound CC1(C)CC(C)(C)CC(C)(N)C1 OGZQTTHDGQBLBT-UHFFFAOYSA-N 0.000 description 1
- 229950004543 neramexane Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 125000001736 nosyl group Chemical group S(=O)(=O)(C1=CC=C([N+](=O)[O-])C=C1)* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- VFTQJKSRDCKVQA-UHFFFAOYSA-N oxan-3-ylmethanol Chemical compound OCC1CCCOC1 VFTQJKSRDCKVQA-UHFFFAOYSA-N 0.000 description 1
- LJSIACTVUWWJNX-UHFFFAOYSA-N oxan-3-ylmethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1COCCC1 LJSIACTVUWWJNX-UHFFFAOYSA-N 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- PVOWRUGDCQOEKO-UHFFFAOYSA-N oxolan-2-yl 3-ethyl-2-methylbenzenesulfonate Chemical compound CCC1=CC=CC(S(=O)(=O)OC2OCCC2)=C1C PVOWRUGDCQOEKO-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- YZPOQCQXOSEMAZ-UHFFFAOYSA-N pbt2 Chemical compound ClC1=CC(Cl)=C(O)C2=NC(CN(C)C)=CC=C21 YZPOQCQXOSEMAZ-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229950003486 ponezumab Drugs 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000004304 potassium nitrite Substances 0.000 description 1
- 235000010289 potassium nitrite Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- YRVIKLBSVVNSHF-JTQLQIEISA-N pozanicline Chemical compound CC1=NC=CC=C1OC[C@H]1NCCC1 YRVIKLBSVVNSHF-JTQLQIEISA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 150000005255 pyrrolopyridines Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- BIXNGBXQRRXPLM-UHFFFAOYSA-K ruthenium(3+);trichloride;hydrate Chemical compound O.Cl[Ru](Cl)Cl BIXNGBXQRRXPLM-UHFFFAOYSA-K 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- NGHMEZWZOZEZOH-UHFFFAOYSA-N silicic acid;hydrate Chemical compound O.O[Si](O)(O)O NGHMEZWZOZEZOH-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 229950007874 solanezumab Drugs 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 description 1
- 229960002876 tegaserod Drugs 0.000 description 1
- HKIGXXRMJFUUKV-QMMMGPOBSA-N tert-butyl (3s)-3-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H](CO)C1 HKIGXXRMJFUUKV-QMMMGPOBSA-N 0.000 description 1
- DNUFVBGZKFHSDQ-MRVPVSSYSA-N tert-butyl (3s)-3-(iodomethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H](CI)C1 DNUFVBGZKFHSDQ-MRVPVSSYSA-N 0.000 description 1
- OJCLHERKFHHUTB-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(CO)C1 OJCLHERKFHHUTB-UHFFFAOYSA-N 0.000 description 1
- YBNJZIDYXCGAPX-UHFFFAOYSA-N tert-butyl 4-(2-hydroxyethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CCO)CC1 YBNJZIDYXCGAPX-UHFFFAOYSA-N 0.000 description 1
- WRCNVYRLKORNCB-UHFFFAOYSA-N tert-butyl 4-(c-chloro-n-hydroxycarbonimidoyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C(Cl)=NO)CC1 WRCNVYRLKORNCB-UHFFFAOYSA-N 0.000 description 1
- 150000003527 tetrahydropyrans Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- ZHMXORQMRMXIII-UHFFFAOYSA-N tri(propan-2-yl)-[2-(3-propan-2-ylindazol-1-yl)ethynyl]silane Chemical compound C1=CC=C2C(C(C)C)=NN(C#C[Si](C(C)C)(C(C)C)C(C)C)C2=C1 ZHMXORQMRMXIII-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-O triethanolammonium Chemical class OCC[NH+](CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-O 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108010084171 vanutide cridificar Proteins 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 229960004751 varenicline Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Definitions
- the present invention relates to a novel indazole- or pyrrolopyridine-derivative which has an agonistic action or a partial agonistic action against serotonin-4 receptor (hereinafter, optionally referred to as 5-HT 4 receptor) , and a pharmaceutical composition comprising the same.
- 5-HT 4 receptor which is a subtype of serotonin receptor has been found in an action mechanism study of metoclopramide [i.e. 4-amino-5-chloro-N- (2-diethylamino- ethyl) -2-methoxybenzamide] which is an enterokinesis- promoting agent or a digestive tract function-improving agent in widespread clinical use (see, Non-patent Reference 1). It has been known that 5-HT 4 receptor agonists promote enterokinesis in the peripheral part, and for example, mosapride, cisapride and tegaserod have already been marketed (provided that the sale of cisapride was stopped after marketing) .
- 5-HT 4 receptor agonists are effective in improving cognitive function by enhancing the acetylcholine release, and in increasing soluble APP a via the activation of a secretase to lower the amount of beta-amyloid protein ( ⁇ ) relatively (see, Non-patent Reference 2) .
- PRX-03140 which acts as a partial agonist to 5-HT 4 receptor has been reported to be efficacious for improving cognitive function and lowering ⁇ in an animal experiment using rats (see, Non-patent Reference 1) .
- PRX-03140 shows the effect for improving cognitive function in a phase II clinical trial with AD patients (see, Non-patent Reference 2) .
- 5-HT 4 receptor agonists are expected to be a medicament having a novel mechanism for treating various dementia caused by Alzheimer-type dementia (AD) and neurodegenerative diseases.
- AD Alzheimer-type dementia
- a super-aging society is coming in the near future, and the number of patients suffering from Alzheimer- type dementia (AD) is increasing rapidly.
- AD Alzheimer- type dementia
- Patent REFERENCE 1 US 2005/197335 Al
- Patent Reference 2 US 2006/135764 Al
- Non-patent Reference 1 37th SFN Meeting (2007) , presentation abstract (poster presentation number 745.10/CCC12)
- Non-patent Reference 2 International Conference on Alzheimer's Disease (ICAD) 2008, presentation abstract, poster presentation number HT-01-07
- the problem to be solved by the present invention is to provide a serotonin-4 receptor agonist useful as a medicament for treating Alzheimer-type dementia and other similar diseases.
- the present inventors have extensively studied the problem and have found that a group of compounds comprising an aromatic-ring moiety of indazole or pyrrolopyridine and a bioisosteric structure of amide bond as a linker moiety to bind the aromatic-ring moiety and an amine side chain (typically, oxadiazole ring) shows an excellent agonistic activity against 5-HT 4 receptors, and thus useful as a medicament for treating Alzheimer-type dementia and similar diseases. Based upon the new findings, the present invention has been completed.
- the present invention can provide indazole derivatives and pyrrolopyridine derivatives of the following Formula (1) (hereinafter, optionally referred to as "the present compound”) .
- a compound of Formula (1) A compound of Formula (1) :
- A is the following Formula (A-l) , Formula (A-2) , Formula (A-3) , or Formula (A-4): lH-(
- 1 is an integer of 0 to 4,
- n is an integer of 0 to 2 ,
- n is an integer of 0 to 2 ,
- o and p are independently an integer of 0 or 1
- q is an integer of 0 to 5
- (A-l) to (A-4) may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of Ci_ 6 alkyl group, C 2 - 6 alkenyl group, C 2-6 alkynyl group, hydroxy group, C 1-6 alkoxy group, and halogen atom at each substitutable position thereof, the following Formula (B-l) , Formula (B-2) , or Formula (B-3) :
- (B-2) and (B-3) may optionally include an unsaturated bond(s) at an acceptable position (s) of the ring,
- R 8 , R 9 and D are independently a group selected from the group consisiting of the following (1) and (2) :
- C 1-6 alkyl group, C 3-6 alkenyl group, C 3-6 alkynyl group, C 3-8 monocyclic, C7-10 bicyclic or C 7 - 12 tricyclic cycloalkyl group, and C 5-8 monocyclic or C 7 _i 0 bicyclic cycloalkenyl group may be independently and optionally substituted with one or more substituents independently- selected from the .group consisting of Ci -4 alkyl group, hydroxy group, d -4 alkoxy group, Ci -4 haloalkyl group, Ci-4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2 . 6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof;
- u is an integer of 0 to 4 provided that when u is an integer of 1 to 4, the alkylene chain may be optionally substituted with one or more substituents independently-selected from the group consisting of Ci - 6 alkyl group, C 2-6 alkenyl group, C 2 -6 alkynyl group, hydroxy group, Ci-6 alkoxy group, oxo group, and halogen atom,
- R 12 is the following Formula (R 12 -l) , Formula (R 12 -2) , Formula (R 12 -3) , Formula (R 12 -4) , Formula (R 12 -5) , Formula (R 12 -6) , Formula (R 1 -7), or Formula (R 12 -8):
- R 12 -5) (R 1 -6) (R 2 -7) (R 12 -8) wherein R 13 is a group selected from the group consisting of the following (1) to (5) :
- Ci -6 alkyl group, C 3-6 alkenyl group, C 3-6 alkynyl group, C 3-8 cycloalkyl group, and C 5-8 cycloalkenyl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of Ci-4 alkyl group, hydroxy group, Ci- 4 alkoxy group, Ci -4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, oxo group, and halogen atom at each substitutable position thereof;
- R 16 is an optionally-substituted Ci-6 alkyl group, an optionally-substituted C 3-6 alkenyl group, an optionally-substituted C 3-6 alkynyl group, an optionally- substituted C 3 - 8 cycloalkyl group, an optionally-substituted C 5 -s cycloalkenyl group, an optionally-substituted aryl group, an optionally- substituted heteroaryl group, an optionally-substituted 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group (wherein the binding site is any one carbon atom in the heterocyclic ring) , or an optionally-substituted 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group (wherein the binding site is any one carbon atom in the heterocyclic ring) ,
- Ci- 6 alkyl group, C 3-6 alkenyl group, C 3 -6 alkynyl group, C 3-8 cycloalkyl group, C 5-8 cycloalkenyl group, 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group, and 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of Ci- 4 alkyl group, hydroxy group, Ci -4 alkoxy group, C 1-4 haloalkyl group, Ci-4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of halogen atom,
- R 17 and R 18 are independently hydrogen atom, Ci- 6 alkyl group, C 3-6 alkenyl group or C 3-6 alkynyl group;
- R 19 and R 20 are independently hydrogen atom or any group defined in the said R 16 , or
- R 19 and R 20 may be taken together with the adjacent nitrogen atom to form a saturated or unsaturated 4- to 8- membered monocyclic nitrogen- containing heterocyclic group comprising additional 0 to 2 heteroatoms independently- selected from the group consisting of 1 to 2 nitrogen atoms, 1 oxygen atom and 1 sulfur atom wherein the heterocyclic group may be optionally substituted with one or more substituents independently-selected from the group consisting of Ci - 4 alkyl group, hydroxy group, Ci- alkoxy group, Ci-4 haloalkyl group, C 1- haloalkoxy group, cyano group, oxo group, and halogen atom at each substitutable position thereof,
- R 14 and R 15 are independently hydrogen atom, an optionally- substituted Ci- 6 alkyl group, an optionally- substituted C 3-6 alkenyl group, an optionally- substituted C 3-6 alkynyl group, an optionally- substituted C 3-8 cycloalkyl group, an optionally-substituted C 5 - 8 cycloalkenyl group, an optionally- substituted aryl group, an optionally- substituted heteroaryl group, an optionally-substituted 5- to 9 -membered monocyclic or 7- to 10 -membered bicyclic non- aromatic unsaturated heterocyclic group (which is attached to the adjacent nitrogen atom via any one carbon atom in the heterocyclic group) , an optionally- substituted 4- to 9- merabered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group (which is attached to the adjacent nitrogen atom via any one carbon atom in the heterocyclic group) , C 2-6 alkanoyl group, Ci
- Ci_ 6 alkyl group, C 3-6 alkenyl group, C 3 - 6 alkynyl group, C 3-8 cycloalkyl group, C 5-8 cycloalkenyl group, 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group, 4- to 9- membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group, C 2- 6 alkanoyl group, Ci -6 alkoxycarbonyl group, and Ci -6 alkylsulfonyl group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of Ci- alkyl group, hydroxy group, Ci_ 4 alkoxy group, cyano group, oxo group, aryl group, heteroaryl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently- selected
- R 14 and R 15 may be taken together with the adjacent nitrogen atom to form a saturated or unsaturated 4- to 9-membered monocyclic or 7- to 10-membered bicyclic nitrogen- containing heterocyclic group comprising additional 0 to 2 heteroatoms independently-selected from the group consisting of 1 to 2 nitrogen atoms, 1 oxygen atom and 1 sulfur atom wherein the heterocyclic group may be optionally substituted with one or more substituents independently-selected from the group consisting of Ci -4 alkyl group, hydroxy group, Ci_ 4 alkoxy group, Ci_ 4 haloalkyl group, Ci-4 haloalkoxy group, cyano group, oxo group, and halogen atom at each substitutable position thereof, (R 12 -l) to (R 12 -4) may optionally include an unsaturated bond(s) at an acceptable position(s) of the ring,
- R 8' and R 9' are independently hydrogen atom, an optionally- substituted Ci-6 alkyl group, an optionally-substituted C 3 - 6 alkenyl group, an optionally- substituted C 3-6 alkynyl group, an optionally-substituted C 3 - 8 cycloalkyl group, an optionally-substituted C 5-8 cycloalkenyl group, an optionally-substituted aryl group, an optionally- substituted heteroaryl group, an optionally-substituted 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non- aromatic unsaturated heterocyclic group (which is attached to the adjacent nitrogen atom via any one carbon atom in the heterocyclic group), or an optionally-substituted 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group (which is attached to the adjacent nitrogen atom via any one carbon atom in the heterocyclic group) ,
- Ci - 6 alkyl group C 3 - 6 alkenyl group, C 3 - 6 alkynyl group, C 3-8 cycloalkyl group, C 5-8 cycloalkenyl group, 5- to 9-membered monocyclic .
- aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of halogen atom, hydroxy group, Ci - 4 alkyl group, Ci- alkoxy group, Ci_ 4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, nitro group,
- R 10 , R 10 ', R 11 and R 11 ' are independently hydrogen atom, halogen atom, hydroxy group, an optionally- substituted Ci -6 alkyl group, an optionally-substituted C 2- 6 alkenyl group, an optionally- substituted C 2 -e alkynyl group, an optionally- substituted Ci-6 alkoxy group, cyano group, or an oxo group, wherein the Ci -6 alkyl group, C 2 -6 alkenyl group, C 2 -e alkynyl group, and C 1-6 alkoxy group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of Ci -4 alkyl group, hydroxy group, C 1-4 alkoxy group, Ci -4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2 -e alkanoyl group, phenacyl group, and halogen
- a pair of R 10 and R 11 , and a pair of R 10 ' and R 11 ' may be independently taken together to form an optionally- substituted saturated or unsaturated 3- to 8-membered ring that may comprise 1 oxygen atom, which may be a bicyclic or a spiro compound with the ring to which the pair of R 10 and R 11 , or R 10 ' and R 11 ' is attached,
- the saturated or unsaturated 3- to 8-membered ring may be optionally substituted with one or more substituents independently- selected from the group consisting of Ci -4 alkyl group, hydroxy group, Ci -4 alkoxy group, Ci-4 haloalkyl group, Ci -4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2- 6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof, r and r ' are independently an integer of 0 to 3 ,
- s and s 1 are independently an integer of 0 to 3
- t and t 1 are independently 1 or 2
- v is an integer of 0 to 2
- V is nitrogen atom or C-R 1 wherein R 1 is hydrogen atom, halogen atom, an optionally-substituted Ci -6 alkyl group, an optionally- substituted C 2 . 6 alkenyl group, an optionally- substituted C 2 -6 alkynyl group, an optionally- substituted C 3-8 cycloalkyl group, an optionally- substituted C 5 - 8 cycloalkenyl group, an optionally- substituted aryl group, or an optionally- substituted heteroaryl group,
- Ci -6 alkyl group, C 2 -e alkenyl group, C 2 -6 alkynyl group, C 3-8 cycloalkyl group, and C 5 - 8 cycloalkenyl group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of Ci -4 alkyl group, hydroxy group, Ci_ 4 alkoxy group, Ci -4 haloalkyl group, Ci -4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2 - alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of halogen atom, hydroxy group, Ci -4 alkyl group, Ci_ 4 alkoxy group, Ci -4 haloalkyl group, Ci-
- Ci- 6 alkyl group, C 2 - 6 alkenyl group, C 2 -6 alkynyl group, C 3-8 cycloalkyl group, C 5 - 8 cycloalkenyl group, Ci-6 alkoxy group, Ci - 4 haloalkyl group, and Ci- 4 haloalkoxy group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of Ci- alkyl group, hydroxy group, Ci - 4 alkoxy group, Ci- 4 haloalkyl group, Ci -4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2-6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of halogen atom, hydroxy group
- V when V is C-R 1 , W is nitrogen atom, and when V is nitrogen atom, W is C-R 2 ,
- U is carbon atom or nitrogen atom
- X, Y and Z are independently selected from the group consisting of oxygen atom, nitrogen atom, sulfur atom and carbon atom, provided that at least one of X, Y and Z is oxygen atom, sulfur atom, or nitrogen atom,
- R 3 is hydrogen atom, halogen atom, an optionally- substituted Ci - 6 alkyl group, an optionally-substituted C 2 - 6 alkenyl group, an optionally-substituted C 2- 6 alkynyl group, an optionally-substituted C 3 - 8 cycloalkyl group, an optionally- substituted C 5 - 8 cycloalkenyl group, an optionally-substituted Ci - 6 alkoxy group, an optionally- substituted Ci -4 haloalkyl group, an optionally-substituted Ci-4 haloalkoxy group, cyano group, nitro group, an optionally-substituted aryl group, an optionally- substituted heteroaryl group, an optionally-substituted 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non- aromatic unsaturated heterocyclic group, or an optionally- substituted 4- to 9 -membered mono
- C 1-6 alkyl group, C 2 - & alkenyl group, C 2 - 6 alkynyl group, C 3-8 cycloalkyl group, C 5 - 8 cycloalkenyl group, Ci-6 alkoxy group, Ci - 4 haloalkyl group, Ci -4 haloalkoxy group, 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group, and 4- to 9- membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of C 1-4 alkyl group, hydroxy group, Ci -4 alkoxy group, C 1-4 haloalkyl group, Ci_ 4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2- 6 alkanoyl group,
- Ci - 6 alkyl group, C 2- 6 alkenyl group, C 2 - 6 alkynyl group, C 3-8 cycloalkyl group, . C 5-8 cycloalkenyl group, Ci-6 alkoxy group, Ci -4 haloalkyl group, and C 1-4 haloalkoxy group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of Ci- alkyl group, hydroxy group, C1-4 alkoxy group, Ci -4 haloalkyl group, Ci_ 4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2 -6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of halogen atom, hydroxy group, Ci-
- R 3 and R 4 may be taken together to form a saturated or unsaturated 6- to 9-membered ring optionally comprising 1 oxygen atom wherein the ring may be optionally substituted with one or more substituents independently- selected from the group consisting of C 1-4 alkyl group, hydroxy group, C 1-4 alkoxy group, Ci_ 4 haloalkyl group, Ci - 4 haloalkoxy group, cyano group, oxo group, and halogen atom at each substitutable position thereof, and
- R 5 and R 6 are independently hydrogen atom, halogen atom, hydroxy group, an optionally-substituted Ci - 6 alkyl group, an optionally-substituted C 2 _ 6 alkenyl group, an optionally- substituted C 2 -6 alkynyl group, an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 5-8 cycloalkenyl group, an optionally-substituted Ci- 6 alkoxy group, an optionally-substituted Ci - 4 haloalkyl group, an optionally-substituted Ci- haloalkoxy group, cyano group, nitro group, an optionally-substituted aryl group, an optionally-substituted heteroaryl group, or an optionally- substituted amino group,
- Ci - 6 alkyl group, C 2 - 6 alkenyl group, C 2 - 6 alkynyl group, C 3-8 cycloalkyl group, C 5-8 cycloalkenyl group, C 1 - 6 alkoxy group, Ci -4 haloalkyl group, and Ci - 4 haloalkoxy group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of Ci- 4 alkyl group, hydroxy group, Ci -4 alkoxy group, Ci- haloalkyl group, C 1 -4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2 -6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of halogen atom,
- A is the following Formula (A-l) , Formula (A-2) , Formula (A-3), or Formula (A-4):
- 1 is an integer of 0 to ,
- n is an integer of 0 to 2
- n is an integer of 0 to 2
- o and p are independently an integer of 0 or 1
- q is an integer of 0 to 5
- (A-1) to (A-4) may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of Ci - 6 alkyl group, C 2 -6 alkenyl group, C 2- 6 alkynyl group, hydroxy group, Ci - 6 alkoxy group, oxo group and halogen atom at each substitutable position thereof,
- B is the following Formula (B-l) , Formula (B-2) , or Formula (B-3):
- (B-2) and (B-3) may optionally include an unsaturated bond(s) at an acceptable position (s) of the ring, and D is absent when B is Formula (B-l) ,
- D is independently a group selected from the group consisting of the following (1) and (2) :
- Ci -6 alkyl group, C 3-6 alkenyl group, C 3-6 alkynyl group, C 3-8 monocyclic, C7-10 bicyclic or C 7-12 tricyclic cycloalkyl group, and C 5-8 monocyclic or C 7-10 bicyclic cycloalkenyl group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of Ci_ 4 alkyl group, hydroxy group, Ci_ 4 alkoxy group, Ci -4 haloalkyl group, Ci-4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2-6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof;
- u is an integer of 0 to 4 provided that when u is an integer of 1 to 4, the alkylene chain may be optionally substituted with one or more substituents independently- selected from the group consisting of Ci- 6 alkyl group, C 2 - 6 alkenyl group, C 2 - 6 alkynyl group, hydroxy group, Ci-6 alkoxy group, oxo group, and halogen atom,
- R 12 is the following Formula (R 12 -l) , Formula (R 12 -2) ,
- R 12 -5) (R 12 -6) (R 2 -7) (R 12 -8) wherein R 13 is a group selected from the group consisting of the following (1) to (5) :
- Ci -6 alkyl group, C 3-6 alkenyl group, C 3-6 alkynyl group, C 3-8 cycloalkyl group, and C 5 _ 8 cycloalkenyl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of Ci_ 4 alkyl group, hydroxy group, Ci -4 alkoxy group, Ci - 4 haloalkyl group, C 1 - 4 haloalkoxy group, cyano group, oxo group, and halogen atom at each substitutable position thereof;
- R 16 is an optionally- substituted Ci - 6 alkyl group, an optionally-substituted C 3 - 6 alkenyl group, an optionally- substituted C 3 - 6 alkynyl group, an optionally- !
- substituted C 3 - 8 cycloalkyl group an optionally- substituted C 5 - 8 cycloalkenyl group, an optionally- substituted aryl group, an optionally-substituted heteroaryl group, an optionally- substituted 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group (wherein the binding site is any one carbon atom in the heterocyclic ring) , or an optionally- substituted 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group (wherein the binding site is any one carbon atom in the heterocyclic ring) ,
- Ci- 6 alkyl group, C 3 - 6 alkenyl group, C 3 - 6 alkynyl group, C 3 - 8 cycloalkyl group, C 5 . 8 cycloalkenyl group, 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group, and 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of Ci -4 alkyl group, hydroxy group, C 1-4 alkoxy group, Ci -4 haloalkyl group, Ci-4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of Ci
- R 17 and R 18 are independently hydrogen atom, Ci- 6 alkyl group, C 3 - 6 alkenyl group or C 3 -6 alkynyl group;
- R 19 and R 20 are independently hydrogen atom or any group defined in the said R 16 , or
- R 19 and R 20 may be taken together with the adjacent nitrogen atom to form a saturated or unsaturated 4- to 8- membered monocyclic nitrogen-containing heterocyclic group comprising additional 0 to 2 heteroatoms independently- selected from the group consisting of 1 to 2 nitrogen atoms, 1 oxygen atom and 1 sulfur atom wherein the heterocyclic group may be optionally substituted with one or more substituents independently-selected from the group consisting of Ci - 4 alkyl group, hydroxy group, Ci_ 4 alkoxy group, Ci - 4 haloalkyl group, Ci_ 4 haloalkoxy group, cyano group, oxo group, and halogen atom at each substitutable position thereof,
- R 14 and R 15 are independently hydrogen atom, an optionally- substituted Ci - 6 alkyl group, an optionally-substituted C 3 - 6 alkenyl group, an optionally-substituted C 3-6 alkynyl group, an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 5-8 cycloalkenyl group, an optionally-substituted aryl group, an optionally- substituted heteroaryl group, an optionally-substituted 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non- aromatic unsaturated heterocyclic group (which is attached to the adjacent nitrogen atom via any one carbon atom in the heterocyclic group) , an optionally-substituted 4- to 9- membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group (which is attached to the adjacent nitrogen atom via any one carbon atom in the heterocyclic group),
- Ci - 6 alkylsulfonyl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of Ci -4 alkyl group, hydroxy group, Ci - 4 alkoxy group, cyano group, oxo group, aryl group, heteroaryl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of halogen atom, hydroxy group, Ci-4 alkyl group, Ci - 4 alkoxy group, cyano group
- R 14 and R 15 may be taken together with the adjacent nitrogen atom to form a saturated or unsaturated 4- to 9-membered monocyclic or 7- to 10-membered bicyclic nitrogen- containing heterocyclic group comprising additional 0 to 2 heteroatoms independently-selected from the group consisting of 1 to 2 nitrogen atoms, 1 oxygen atom and 1 sulfur atom wherein the heterocyclic group may be optionally substituted with one or more substituents independently- selected from the group consisting of C 1-4 alkyl group, hydroxy group, Ci -4 alkoxy group, Ci -4 haloalkyl group, Ci-4 haloalkoxy group, cyano group, oxo group, and halogen atom at each substitutable position thereof,
- (R 12 -l) to (R 12 -4) may optionally include an unsaturated bond(s) at an acceptable position (s) of the ring,
- R 8 , R 8' , R 9 and R 9 ' are independently hydrogen atom, an optionally-substituted C 1-6 alkyl group, an optionally- substituted C 3 -6 alkenyl group, an optionally-substituted C 3-6 alkynyl group, an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 5-8 cycloalkenyl group, an optionally-substituted aryl group, an optionally- substituted heteroaryl group, an optionally-substituted 5- to 9-membered monocyclic or 7 ⁇ to 10-membered bicyclic non- aromatic unsaturated heterocyclic group (which is attached to the adjacent nitrogen atom via any one carbon atom in the heterocyclic group) , or an optionally-substituted 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group (which is attached to the adjacent nitrogen atom via any one
- a pair of R 10 and R 11 , and a pair of R 10' and R 11' may be independently taken together to form an optionally- substituted saturated or unsaturated 3- to 8-membered ring that may comprise 1 oxygen atom, which may be a bicyclic or a spiro compound with the ring to which the pair of R 10 and R 11 is attached,
- the saturated or unsaturated 3- to 8-membered ring may be optionally substituted with one or more substituents independently-selected from the group consisting of C 1 - 4 alkyl group, hydroxy group, Ci -4 alkoxy group, Ci- haloalkyl group, Ci -4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2 -6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof, r and r' are independently an integer of 0. to 3,
- s and s' are independently an integer of 0 to 3
- t and t 1 are independently 1 or 2 ,
- v is an integer of 0 to 2 ,
- V is nitrogen atom or C-R 1 wherein R 1 is hydrogen atom, halogen atom, an optionally-substituted Ci - e alkyl group, an optionally-substituted C 2 - 6 alkenyl group, an optionally- substituted C 2- 6 alkynyl group, an optionally-substituted C 3 -8 cycloalkyl group, an optionally-substituted C 5-8 cycloalkenyl group, an optionally-substituted aryl group, or an optionally-substituted heteroaryl group, wherein the Ci - 6 alkyl group, C 2 - 6 alkenyl group, C 2 -6 alkynyl group, C 3 - 8 cycloalkyl group, and C 5 - 8 cycloalkenyl group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of Ci- 4 alkyl group,
- W is nitrogen atom or C-R 2 wherein R 2 is hydrogen atom, halogen atom, hydroxy group, an optionally-substituted Ci_ 6 alkyl group, an optionally-substituted C 2- 6 alkenyl group, an optionally-substituted C 2-6 alkynyl group, an optionally- substituted C 3-8 cycloalkyl group, an optionally-substituted C 5 -8 cycloalkenyl group, an optionally-substituted Ci - 6 alkoxy group, an optionally-substituted Ci - 4 haloalkyl group, an optionally- substituted Ci - 4 haloalkoxy group, cyano group, nitro group, an optionally- substituted aryl group, an optionally-substituted heteroaryl group, or an optionally- substituted amino group,
- Ci- 6 alkyl group, C 2 - 5 alkenyl group, C 2 - 6 alkynyl group, C 3 , 8 cycloalkyl group, C 5-8 cycloalkenyl group, Ci-6 alkoxy group, Ci -4 haloalkyl group, and Ci- haloalkoxy group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of C 1 -4 alkyl group, hydroxy group, Ci - 4 alkoxy group, Ci_ 4 haloalkyl group, Ci_ 4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2 - 6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of halogen atom,
- V when V is C-R 1 , W is nitrogen atom, and when V is nitrogen atom, W is C- R 2 , U is carbon atom or nitrogen atom, X, Y and Z are independently selected from the group consisting of oxygen atom, nitrogen atom, sulfur atom and carbon atom, provided that at least one of X, Y and Z is oxygen atom, sulfur atom, or nitrogen atom,
- R 3 is hydrogen atom, halogen atom, an optionally- substituted Ci-6 alkyl group, an optionally- substituted C 2 -6 alkenyl group, an optionally-substituted C 2 -e alkynyl group, an optionally- substituted C 3 - 8 cycloalkyl group, an optionally- substituted C 5-8 cycloalkenyl group, an optionally- substituted Ci_ 6 alkoxy group, an optionally- substituted Ci-4 haloalkyl group, an optionally- substituted Ci-4 haloalkoxy group, cyano group, nitro group, an optionally- substituted aryl group, an optionally- substituted heteroaryl group, an optionally- substituted 5- to 9 -membered monocyclic or 7- to 10 -membered bicyclic non- aromatic unsaturated heterocyclic group, or an optionally- substituted 4- to 9 -membered monocyclic or 7- to 10- membered bicyclic saturated heterocyclic group,
- Ci - 6 alkyl group, C 2- 6 alkenyl group, C 2 -e alkynyl group, C 3-8 cycloalkyl group, C 5-8 cycloalkenyl group, Ci-6 alkoxy group, Ci - 4 haloalkyl group, Ci- haloalkoxy group, 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group, and 4- to 9- membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of Ci_ 4 alkyl group, hydroxy group, C 1-4 alkoxy group, Ci- haloalkyl group, Ci -4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2-6 alkanoyl group, phenacyl group, and
- R 4 is hydrogen atom, halogen atom, hydroxy group, an optionally- substituted Ci_ 6 alkyl group, an optionally- substituted C 2 -6 alkenyl group, an optionally- substituted C 2 -6 alkynyl group, an optionally- substituted C 3-8 cycloalkyl group, an optionally- substituted C 5-8 cycloalkenyl group, an optionally-substituted Ci -6 alkoxy group, an optionally- substituted Ci -4 haloalkyl group, an optionally- substituted Ci- 4 haloalkoxy group, cyano group, nitro group, an optionally-substituted aryl group, an optionally- substituted heteroaryl group, or an optionally- substituted amino group,
- Ci- 6 alkyl group, C 2 - 6 alkenyl group, C 2 -6 alkynyl group, C3-8 cycloalkyl group, C 5-8 cycloalkenyl group, Ci-6 alkoxy group, Ci -4 haloalkyl group, and C 1 -4 haloalkoxy group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of C 1- 4 alkyl " group, hydroxy group, Ci- 4 alkoxy group, Ci -4 haloalkyl group, Ci_ 4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2 -6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of halogen atom, hydroxy
- R 3 and R 4 may be taken together to form a saturated or unsaturated 6- to 9-membered ring optionally comprising 1 oxygen atom wherein the ring may be optionally substituted with one or more substituents independently-selected from the group consisting of Ci_ alkyl group, hydroxy group, Ci- 4 alkoxy group, Ci- haloalkyl group, Ci - 4 haloalkoxy group, cyano group, oxo group, and halogen atom at each substitutable position thereof, and
- R 5 and R 6 are independently hydrogen atom, halogen atom, hydroxy group, an optionally-substituted Ci - 6 alkyl group, an optionally-substituted C 2-6 alkenyl group, an optionally- substituted C 2 -6 alkynyl group, an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 5-8 cycloalkenyl group, an optionally-substituted Ci - 6 alkoxy group, an optionally-substituted Ci - 4 haloalkyl group, an optionally-substituted C X - 4 haloalkoxy group, cyano group, nitro group, an optionally-substituted aryl group, an optionally-substituted heteroaryl group, or an optionally- substituted amino group,
- Ci - 6 alkyl group, C 2 - 6 alkenyl group, C 2 - 6 alkynyl group, C 3-8 cycloalkyl group, C 5-8 cycloalkenyl group, Ci-6 alkoxy group, C 1-4 haloalkyl group, and Ci - 4 haloalkoxy group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of Ci -4 alkyl group, hydroxy group, Ci_ 4 alkoxy group, C 1- 4 haloalkyl group, Ci - 4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2- 6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of halogen atom,
- the compound of Term 2 or a pharmaceutically acceptable salt thereof wherein the Formulae (A-l) to (A-4) may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of C 1-s alkyl group, C 2 -6 alkenyl group, C 2 - 6 alkynyl group, hydroxy group, Ci- 6 alkoxy group, and halogen atom at each substitutable position thereof.
- R 3 is hydrogen atom, halogen atom, an optionally-substituted Ci - 6 alkyl group, an optionally-substituted C 2- 6 alkenyl group, an optionally-substituted C 2-6 alkynyl group, an optionally- substituted C 3-8 cycloalkyl group, or an optionally- substituted C 5-8 cycloalkenyl group.
- the compound of Term 1 which is selected from the group consisting of the following compounds or a pharmaceutically acceptable salt thereof:
- a pharmaceutical composition comprising the compound of any one of Terms 1 to 18 or a pharmaceutically acceptable salt thereof .
- a serotonin-4 receptor agonist comprising the compound of any one of Terms 1 to 18 or a pharmaceutically acceptable salt thereof as an active ingredient.
- a medicament for treating Alzheimer-type dementia comprising the compound of any one of Terms 1 to 18 or a pharmaceutically acceptable salt thereof as an active ingredient .
- Term 22 A method for treating a diesease associated with serotonin-4 receptor comprising administering a therapeutically effective amount of the compound of any one of Terms 1 to 18 or a pharmaceutically acceptable salt thereof to a patient in need thereof.
- a method for treating Alzheimer-type dementia comprising administering a therapeutically effective amount of the compound of any one of Terms 1 to 18 or a pharmaceutically acceptable salt thereof to a patient in need thereof .
- the present invention can provide compounds which act as an agonist or a partial agonist to a serotonin-4 receptor (hereinafter, optionally referred to as a 5-HT receptor) , and thus can provide a medicament for treating or preventing diseases or symptoms associated with serotonin-4 receptor.
- a serotonin-4 receptor hereinafter, optionally referred to as a 5-HT receptor
- the diseases or symptoms suggested to be associated with serotonin-4 receptor include the following (i) to (v) :
- neuropsychiatry diseases such as Alzheimer-type dementia, Lewy body dementia, vascular dementia, depression, posttraumatic stress disorder (PTSD) , memory impairment, anxiety, and schizophrenia;
- digestive system diseases such as irritable bowel syndrome, atonic constipation, habitual constipation, chronic constipation, constipation induced by drugs (e.g. morphine and antipsychotic drugs) , constipation associated with Parkinson's disease, constipation associated with multiple sclerosis, constipation associated with diabetes mellitus, and constipation or dyschezia caused by contrast materials taken as a pretreatment for endoscopic examinations or barium enema X-ray examinations;
- drugs e.g. morphine and antipsychotic drugs
- digestive system diseases such as functional dyspepsia, acute/chronic gastritis, reflux esophagitis, gastric ulcer, duodenal ulcer, gastric neurosis, postoperative paralytic ileus, senile ileus, non-erosive reflux disease, NSAID ulcer, diabetic gastroparesis , postgastrectomy syndrome, and intestinal pseudoobstruction;
- digestive system symptoms such as the digestive system diseases mentioned in the above (ii) and (iii) , scleroderma, diabetes mellitus, anorexia in esophageal/biliary-tract diseases, nausea, emesis, bloating, epigastric discomfort, abdominal pain, heartburn, and belching; and
- urinary system diseases associated with dysuria such as urinary tract obstruction and prostatic hyperplasia.
- the present compound is useful as a medicament for treating or preventing especially the neuropsychiatric diseases such as Alzheimer-type dementia mentioned in the above (i) because the compound shows an excellent 5-HT 4 receptor agonist activity and brain penetration.
- Ci-6 alkyl group used herein includes a straight- or branched-chain alkyl group having 1 to 6 carbon atoms; and specifically methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, hexyl group, etc.
- the Ci . 6 alkyl group includes preferably C 1-4 alkyl group; and specifically methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec -butyl group, and tert-butyl group.
- the "C 2 - 6 alkenyl group” used herein includes a straight- or branched-chain alkenyl group having 2 to 6 carbon atoms and 1 to 2 double bonds .
- the C 2 - 6 alkenyl group includes specifically ethenyl group, 1-propenyl group
- the "C 2 - 6 alkynyl group” used herein includes a straight- or branched-chain alkynyl group having 2 to 6 carbon atoms and 1 to 2 triple bonds, and more preferably 1 triple bond.
- the C 2 - s alkynyl group includes specifically ethynyl group, 1-propynyl group, 2-propynyl group, 1- butynyl group, 1-methyl-2 -propynyl group, 3 -butynyl group,
- 2-butynyl group 1-pentynyl group, 1-ethyl -2 -propynyl group, 4-pentynyl group, 3-pentynyl group, 2-pentynyl group, 1- methyl-2 -butynyl group, 1-hexynyl group, 2-hexynyl group,
- the " Ci - 6 alkoxy group" used herein includes a straight- or branched-chain alkoxy group having 1 to 6 carbon atoms.
- the Ci . 6 alkoxy group includes specifically methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, pentyloxy group, hexyloxy group etc.; and preferably methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, sec-butoxy group, and tert-butoxy group.
- halogen atom used herein includes fluorine atom, chlorine atom, bromine atom and iodine atom; preferably fluorine atom and chlorine atom; and more preferably fluorine atom.
- the "C 3-6 alkenyl group” used herein includes a straight- or branched-chain alkenyl group having 3 to 6 carbon atoms and 1 to 2 double bonds.
- the C 3 . 6 alkenyl group includes specifically 1-propenyl group, 1-methylvinyl group, 2-propenyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 2-methyl-1-propenyl group, 2-methyl-2- propenyl group, 1-pentenyl group, 2-pentenyl group, 3- pentenyl group, 4-pentenyl group, 2 -methyl-1-butenyl group, 2 -methyl-2-butenyl group, 2 -methyl-3-butenyl group, 1- hexenyl group, 2-hexenyl group, 3-hexenyl group, 4-hexenyl group, 5-hexenyl group, 2 -methyl-1-pentenyl group, 2- propyl-2 -propenyl group, 1-e
- the "C 3 . g alkynyl group” used herein includes a straight- or branched-chain alkynyl group having 3 to 6 carbon atoms and 1 to 2 triple bonds, and more preferably 1 triple bond.
- the C 3 _ 6 alkynyl group includes specifically 1-propynyl group, 2-propynyl group, 1-butynyl group, 1- methyl-2-propynyl group, 3-butynyl group, 2-butynyl group, 1-pentynyl group, 1-ethyl-2-propynyl group, 4-pentynyl group, 3-pentynyl group, 2-pentynyl group, l-methyl-2- butynyl group, 1-hexynyl group, 2-hexynyl group, 3-hexynyl group, 4-hexynyl group, 5-hexynyl group, etc; and preferably 1-propynyl group, 2-propynyl group
- C 3 - 8 cycloalkyl group used herein includes a 3- to 8-membered cycloalkyl group; specifically cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group, etc.; and preferably cyclopropyl group, cyclobutyl group, cyclopentyl group, and cyclohexyl group.
- the "C 5 - 8 cycloalkenyl group” used herein includes a 5- to 8-membered cycloalkenyl group; specifically 1- cyclopentenyl group, 3-cyclopentenyl group, -cyclopentenyl group, 1-cyclohexenyl group, 3 -cyclohexenyl group, 4- cyclohexenyl group, 1-cycloheptenyl group, 3 -cycloheptenyl group, 4 -cycloheptenyl group, 5-cycloheptenyl group, 1- cyclooctenyl group, 3-cyclooctenyl group, 4-cyclooctenyl group, 5-cyclooctenyl group, etc.; and preferably 1- cyclopentenyl group, 3-cyclopentenyl group, 4 -cyclopentenyl group, 1-cyclohexenyl group, 3 -cyclohexenyl group, and 4- cyclohexenyl group.
- aryl group used herein includes a 6- to 10- membered monocyclic or bicyclic aryl group; and specifically phenyl group, 1-naphthyl group, 2-naphthyl group, etc .
- heteroaryl group used herein includes a 5- to 10-membered monocyclic or bicyclic heteroaryl group comprising 1 to 4 heteroatoms selected from the group consisting of 1 to 3 nitrogen atoms, 1 oxygen atom and 1 sulfur atom.
- the monocyclic heteroaryl group includes specifically pyrrolyl group, imidazolyl group, triazolyl group, tetrazolyl group, furyl group, thienyl group, oxazolyl group, thiazolyl group, pyridyl group, pyrimidinyl group, pyrazinyl group, pyridazinyl group, triazinyl group, etc.; and preferably pyrrolyl group, imidazolyl group, triazolyl group, tetrazolyl group, furyl group, thienyl group, oxazolyl group, pyridyl group, pyrimidinyl group, pyrazinyl group, and pyridazinyl group.
- the bicyclic heteroaryl group includes indolyl group, benzofuryl group, benzothienyl group, quinolinyl group, benzisoxazolyl group, etc.
- the binding site of the heteroaryl group is not limited and may be any carbon atom or nitrogen atom therein as long as the bond is chemically stable.
- the heteroaryl .group includes preferably indolyl group and quinolinyl group.
- the "5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group" used herein includes a 5- to 9-membered monocyclic or 7- to 10- membered bicyclic non-aromatic unsaturated heterocyclic group comprising 1 to 4 heteroatoms selected from the group consisting of 1 to 3 nitrogen atoms, 1 oxygen atom and 1 sulfur atom.
- the monocyclic non-aromatic unsaturated heterocyclic group includes a 5-membered non-aromatic unsaturated heterocyclic group having 1 double bond and a 6- or 7-membered non-aromatic unsaturated heterocyclic group having 1 or 2 double bonds; and specifically pyrrolinyl group, 2 , 5-dihydrofuryl group, etc.
- the bicyclic non-aromatic unsaturated heterocyclic group includes a 7- to 10-membered non-aromatic unsaturated heterocyclic group which can be obtained by replacing one or more double bonds of the bicyclic heteroaryl group with single bonds; and specifically 2 , 3 -dihydrobenzofuryl group, 2 , 3-dihydrobenzothienyl group, etc.
- the binding site of the non-aromatic unsaturated heterocyclic group is not limited and may be any carbon atom or nitrogen atom therein as long as the bond is chemically stable.
- the "4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group" used herein includes a 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group comprising 1 to 4 heteroatoms selected from the group consisting of 1 to 4 nitrogen atoms, 1 oxygen atom and 1 sulfur atom.
- the monocyclic saturated heterocyclic group includes specifically azetidinyl group, pyrrolidinyl group, tetrahydrofuryl group, tetrahydrothienyl group, piperazinyl group, piperidinyl group, morpholinyl group, thiomorpholinyl group, tetrahydropyranyl group, hexahydroazepinyl group, 1,4- hexahydrooxazepinyl group, 1, 4 -hexahydrodiazepinyl group, etc.; and preferably azetidinyl group, pyrrolidinyl group, tetrahydrofuryl group, piperazinyl group, piperidinyl group, morpholinyl group, and tetrahydropyranyl group.
- the bicyclic saturated heterocyclic grou includes a 7- to 10- membered saturated heterocyclic group; and specifically quinuclidinyl group, etc.
- the saturated heterocyclic group substituted with oxo group includes specifically 2-oxopyrrolidinyl group, 2 -oxotetrahydrofuryl group, etc.
- the binding site of the saturated heterocyclic group is not limited and may be any carbon atom or nitrogen atom therein as long as the bond is chemically stable.
- Ci-4 alkyl group used herein includes a straight- or branched-chain alkyl group having 1 to 4 carbon atoms; specifically methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group etc.; and preferably methyl group, ethyl group, propyl group, and isopropyl group.
- Ci- alkoxy group used herein includes a straight- or branched-chain alkoxy group having 1 to 4 carbon atoms; specifically methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group etc.; and preferably methoxy group, ethoxy group, propoxy group, isopropoxy group, and tert-butoxy group.
- Ci-4 haloalkoxy group used herein includes an alkoxy group having 1 to 4 carbon atoms which is substituted with the same or a different 1 to 5 halogen atoms; specifically fluoromethoxy group, difluoromethoxy group, trifluoromethoxy group, pentafluoroethoxy group, 2- fluoroethoxy group, 2 , 2-difluoroethoxy group, etc.; and preferably trifluoromethoxy group and pentafluoroethoxy group.
- Ci-4 haloalkyl group used herein includes an alkyl group having 1 to 4 carbon atoms which is substituted with the same or a different 1 to 5 halogen atoms; specifically fluoromethyl group, difluoromethyl group, trifluoromethyl group, 2-fluoroethyl group, 2,2- difluoroethyl group, 4-fluoro butyl group, etc.; and preferably fluoromethyl group, difluoromethyl group, and trifluoromethyl group.
- aryloxy group used herein includes an aryloxy group having 6 to 10 carbon atoms; and specifically phenoxy group, naphthoxy group etc.
- C 2 - 6 alkanoyl group used herein includes a straight- or branched-chain alkanoyl group having 2 to 6 carbon atoms; specifically acetyl group, propanoyl group, butanoyl group, 2-methylpropanoyl group, pentanoyl group, 3 -methylbutanoyl group, 2 -methylbutanoyl group, hexanoyl group, etc.; and preferably acetyl group, propanoyl group, butanoyl group, and 2-methylpropanoyl group.
- the "optionally- substituted amino group” used herein includes, for example, amino, mono- or di- substituted amino, and 4- to 7-membered cyclic amino.
- the substituents of the "mono- or di-substituted amino” includes, for example, "Ci_ 6 alkyl", “C 3 - 7 cycloalkyl", “C 3 _ 7 cycloalkyl Ci . 4 alkyl", etc.
- the "monosubstituted amino” includes, for example, "mono Ci - 6 alkylamino” such as methylamino, ethylamino, propylamino, 1-methylethylamino, butylamino, 2- methylpropylamino, 1-methylpropylamino, and 1,1- dimethylethylamino; "C 3 - 7 cycloalkyl amino” such as cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino, and cycloheptylamino; and " (C 3 .
- cycloalkyl Ci - 4 alkyl) amino such as cyclopropylmethyl- amino, cyclobutylmethylamino, cyclopentylmethylamino, cyclohexylmethylamino, and cycloheptylmethylamino .
- the "di-substituted amino” includes, for example, "di- C . 6 alkylamino” such as dimethylamino, diethylamino, dipropylamino, di-l-methylethylamino, dibutylamino, di-2- methylpropylamino, di-l-raethylpropylamino, and di-1,1- dimethylethylamino; and "iV- ( Ci - 6 alkyl) -N- ( C 3 .
- cycloalkyl) amino such as methylcyclopropylamino, methyl- cyclobutylamino, methylcyclopentylamino, methylcyclo- hexylamino, and methylcycloheptylamino.
- the "4- to 7-membered cyclic amino group” includes, for example, a 4- to 7-membered monocyclic amino group comprising additional 0 to 2 heteroatoms independently- selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom; and the binding site thereof is the nitrogen atom in the ring.
- the optionally- substituted amino group includes, for example, azetidino, pyrrolidino, piperazino, piperidino, morpholino, thiomorpholino, azepano, and oxoazepano; preferably amino, methylamino, ethylamino, cyclopropylamino, cyclobutylamino, dimethylamino, di-l- methylethylamino, methylcyclopropylamino, azetidino, pyrrolidino, piperazino, piperidino, and morpholino; and more preferably amino, methylamino, dimethylamino, azetidino, pyrrolidino, and piperidino.
- the "saturated or unsaturated 4- to 9-membered monocyclic or 7- to 10-membered bicyclic nitrogen- containing heterocyclic group comprising the adjacent nitrogen atom and additional 0 to 2 heteroatoms independently-selected from the group consisting of 1 to 2 nitrogen atoms, 1 oxygen atom and 1 sulfur atom” used herein includes specifically azetidinyl group, pyrrolidinyl group, piperazinyl group, piperidinyl group, morpholinyl group, thiomorpholinyl group, hexahydroazepinyl group, 1,4- hexahydrooxazepinyl group, 1, 4 -hexahydrodiazepinyl group, indolinyl group, isoindolinyl group, 1,2,3,4- tetrahydroquinolinyl group, 1 , 2 , 3 , 4 -tetrahydroisoquinolinyl group, 1 , 2 , 3 , 4 -
- the "saturated or unsaturated 3- to 8-membered ring that may comprise 1 oxygen atom” used herein includes specifically cyclopropane ring, cyclobutane ring, cyclopentane ring, cyclohexane ring, cycloheptane ring, cyclooctane ring, oxetane ring, tetrahydrofuran ring, tetrahydropyran ring, oxepane ring, benzene ring, etc.; and preferably cyclopropane ring, cyclobutane ring, cyclopentane ring, and cyclohexane ring.
- the "bicyclic or a spiro compound in which the above- mentioned ring is attached with the pair of R 10 and R 11 , or R 10' and R 11' " used herein includes specifically indoline, isoindoline, 1, 2, 3, 4-tetrahydroquinoline, 1 , 2 , 3 , 4 -tetra- hydroisoquinoline, 3 -azabicyclo [3.2.0] heptane , 7-aza- bicyclo [2.2.1] heptane, 6-azabicyclo [3.1.1] heptane, 2-aza- bicyclo [2.2.1] heptane, 3 -azabicyclo [3.1.1] heptane, 8-aza- bicyclo [3.2.1] octane, 2 -azabicyclo [2.2.2] octane , 3-aza- bicyclo [3.2.1] octane , octahydroisoindone , octahydro
- C 3-8 monocyclic, C 7 . 10 bicyclic or C 7 . 12 tricyclic cycloalkyl group used herein includes 3- to 8- membered monocyclic cycloalkyl group, 7- to 10-membered bicyclic cycloalkyl group, or 7- to 12-membered tricyclic cycloalkyl group, respectively.
- the monocyclic cycloalkyl group used herein includes specifically cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group, etc.; and preferably cyclopropyl group, cyclobutyl group, cyclopentyl group, and cyclohexyl group.
- the bicyclic cycloalkyl group used herein includes specifically octahydropentalenyl group, octahydro-lH- indenyl ' group, bicyclo [2.2.1] heptyl group, bicyclo [2.2.2] octyl group, bicyclo [4.2.0] octyl group, decahydronaphthalenyl group, etc.; and preferably bicyclo [2.2.1] heptyl group and bicyclo [2.2.2] octyl group.
- the tricyclic cycloalkyl group used herein includes specifically adamantyl group, etc.
- C 5 - 8 monocyclic or C 7 . i 0 bicyclic cycloalkenyl group used herein includes 5- to 8-membered monocyclic cycloalkenyl group or 7- to 10-membered bicyclic cycloalkenyl group, respectively.
- the monocyclic cycloalkenyl group used herein includes specifically 1-cyclopentenyl group, 3-cyclopentenyl group, 4 -cyclopentenyl group, 1-cyclohexenyl group, 3 -cyclohexenyl group, 4-cyclohexenyl group, 1-cycloheptenyl group, 3- cycloheptenyl group, 4-cycloheptenyl group, 5 -cycloheptenyl group, 1-cyclooctenyl group, 3 -cyclooctenyl group, 4- cyclooctenyl group, 5 -cyclooctenyl group, etc; preferably 1-cyclopentenyl group, 3-cyclopentenyl group, 4-cyclo- pentenyl group, 1-cyclohexenyl group, 3 -cyclohexenyl group, and 4 -cyclohexenyl group.
- the bicyclic cycloalkenyl group used herein includes specifically bicyclo [2.2.1] hept-2-enyl group, bicyclo- [2.2.2] oct-2-enyl group, etc.
- the saturated monocyclic nitrogen-containing heterocyclic group includes specifically azetidinyl group, pyrrolidinyl group, piperazinyl group, piperidinyl group, morpholinyl group, thiomorpholinyl group, hexahydroazepinyl group, 1,4- hexahydrooxazepinyl group, etc.; and preferably azetidinyl group, pyrrolidinyl group, piperazinyl group, piperidinyl group, and morpholinyl group.
- the unsaturated monocyclic nitrogen-containing heterocyclic group includes specifically pyrrolyl group, imidazolyl group, triazolyl group, tetrazolyl group, 1,2,3, 6 -tetrahydropyridyl group, 2 , 5 -dihydro-lH-pyrrolyl group, etc.
- Ci- 6 alkoxycarbonyl group used herein includes a carbonyl group having a straight- or branched-chain alkoxy group having 1 to 6 carbon atoms; specifically methoxycarbonyl group, ethoxycarbonyl group, propoxycarbonyl group, isopropoxycarbonyl group, butoxycarbonyl group, isobutoxycarbonyl group, sec- butoxycarbonyl group, tert-butoxycarbonyl group, pentyloxycarbonyl group, hexyloxycarbonyl group etc.; and preferably methoxycarbonyl group, ethoxycarbonyl group, propoxycarbonyl group, isopropoxycarbonyl group, butoxycarbonyl group, isobutoxycarbonyl group, sec- butoxycarbonyl group, and tert-butoxycarbonyl group.
- Ci- 6 alkylsulfonyl group used herein includes a straight- or branched-chain alkylsulfonyl group having 1 to 6 carbon atoms; specifically methylsulfonyl group, ethylsulfonyl group, propylsulfonyl group, isopropyl sulfonyl group, butylsulfonyl group, isobutylsulfonyl group, sec-butylsulfonyl group, tert-butylsulfonyl group, pentylsulfonyl group, hexylsulfonyl group, etc.; and preferably methylsulfonyl group, ethylsulfonyl group, propylsulfonyl group, isopropyl sulfonyl group, butylsulfonyl group, isobutylsulfonyl group, sec-
- the "saturated or unsaturated 6- to 9-membered ring optionally comprising 1 oxygen atom formed by taking R 3 and R 4 together" used herein includes specifically the 6- to 9- membered ring of the following Formulae (E-l) to (E-16) :
- U is carbon atom or nitrogen atom; and X, Y and Z are independently selected from the group consisting of oxygen atom, nitrogen atom, sulfur atom and carbon atom, provided that at least one of X, Y and Z is oxygen atom, sulfur atom, or nitrogen atom” includes heteroaryl of the followin Formulae (F-1) to (F-16) :
- the binding site of the heteroaryl is not limited and may be any carbon atom or nitrogen atom therein as long as the bond is chemically stable.
- the heteroaryl includes preferably Formulae (F-10) to (F-13), and more preferably Formulae (F-10) to (F-ll) .
- the "A” used herein includes preferably Formula (A-1) and Formula (A-3) , and more preferably Formula (A-1) .
- the "B” used herein includes preferably Formula (B-l) and Formula (B-2) , and more preferably Formula (B-2) .
- R 8 , R 9 and D used herein independently include preferably hydrogen atom, an optionally-substituted C x . 6 alkyl group, an optionally-substituted C 3-8 monocyclic, C 7-10 bicyclic or C 7 - 12 tricyclic cycloalkyl group, and - (CH 2 ) U - R 12 .
- the » 12» used herein includes preferably Formula (R 12 -l), Formula (R 12 -3), and Formula (R 12 - 5 ) .
- the » R 13 » used herein includes preferably hydrogen atom, an optionally-substituted C x _ 6 alkyl group, an optionally-substituted C 3 - 8 cycloalkyl group, -COR 16 , S0 2 R 16 , -COOR 16 , and -CONR 19 R 20 ; more preferably an optionally-substituted Ci . 6 alkyl group, an optionally- substituted C 3 - a cycloalkyl group, -COR 16 , -S0 2 R 16 , and - COOR 16 ; and even more preferably -COR 16 , -S0 2 R 16 , and - COOR 16 .
- R 16 used herein includes preferably an optionally-substituted C x . 6 alkyl group, an optionally- substituted C 3 . 8 cycloalkyl group, an optionally- substituted aryl group, and an optionally-substituted heteroaryl group; and more preferably an optionally- substituted C x - 6 alkyl group and an optionally- substituted C 3 - 8 cycloalkyl group.
- R 14 and R 15 used herein independently include preferably hydrogen atom, an optionally-substituted Ci . 6 alkyl group, an optionally-substituted C 3 . 8 cycloalkyl group, an optionally-substituted aryl group, and an optionally-substituted heteroaryl group; and more preferably an optionally-substituted Ci . 6 alkyl group and an optionally-substituted C 3 . 8 cycloalkyl group.
- R 1 used herein includes preferably hydrogen atom, halogen atom, an optionally-substituted C x - 6 alkyl group, and an optionally- substituted C 3 . 8 cycloalkyl group; and more preferably hydrogen atom.
- R 2 used herein includes preferably hydrogen atom, halogen atom, hydroxy group, an optionally-substituted Ci . 6 alkyl group, an optionally-substituted C 3 _ 8 cycloalkyl group, an optionally-substituted Ci _ 6 alkoxy group, an optionally-substituted Ci_ 4 haloalkyl group, an optionally- substituted Ci-4 haloalkoxy group, cyano group, nitro group, an optionally-substituted aryl group, an optionally- substituted heteroaryl group, and an optionally-substituted amino group; more preferably hydrogen atom, halogen atom, an optionally-substituted C x .
- R 3 used herein includes preferably hydrogen atom, halogen atom, an optionally-substituted Ci . 6 alkyl group, and an optionally-substituted C 3 . 8 cycloalkyl group; and more preferably hydrogen atom, halogen atom, and an optionally-substituted Ci . 6 alkyl group.
- R 4 used herein includes preferably hydrogen atom, halogen atom, hydroxy group, an optionally-substituted Ci . 6 alkyl group, an optionally-substituted C 3 _ 8 cycloalkyl group, an optionally-substituted Ci . 6 alkoxy group, an optionally-substituted Ci - 4 haloalkyl group, an optionally- substituted Ci-4 haloalkoxy group, cyano group, nitro group, an optionally-substituted aryl group, an optionally- substituted heteroaryl group, and an optionally-substituted amino group; more preferably hydrogen atom, halogen atom, an optionally-substituted Ci .
- R 5 used herein includes preferably hydrogen atom, halogen atom, hydroxy group, an optionally-substituted Ci . 6 alkyl group, an optionally- substituted C 3 . 8 cycloalkyl group, an optionally-substituted Ci . 6 alkoxy group, an optionally-substituted Ci - 4 haloalkyl group, an optionally- substituted Ci-4 haloalkoxy group, cyano group, nitro group, an optionally-substituted aryl group, an optionally- substituted heteroaryl group, and an optionally-substituted amino group; more preferably hydrogen atom, halogen atom, an optionally-substituted C x .
- R 6 used herein includes preferably hydrogen atom, halogen atom, hydroxy group, an optionally-substituted Ci . 6 alkyl group, an optionally-substituted C 3 _ 8 cycloalkyl group, an optionally- substituted C x _ 6 alkoxy group, an optionally- substituted Ci - 4 haloalkyl group, an optionally- substituted Ci-4 haloalkoxy group, cyano group, nitro group, an optionally- substituted aryl group, an optionally- substituted heteroaryl group, and an optionally- substituted amino group; more preferably hydrogen atom, halogen atom, an optionally-substituted Ci .
- R 8 ' and R 9 ' used herein independently include preferably hydrogen atom, an optionally- substituted Ci . 6 alkyl group, an optionally- substituted C 3 - 8 cycloalkyl group, an optionally-substituted C 5 . 8 cycloalkenyl group, an optionally- substituted aryl group, and an optionally- substituted heteroaryl group; and more preferably an optionally-substituted C x _ 6 alkyl group and an optionally- substituted C 3 - 8 cycloalkyl group.
- the "1" used herein includes an integer of preferably 0 and 1.
- the "m” used herein includes an integer of preferably 0 and 1.
- n used herein includes an integer of preferably 0 and 1.
- the "o" used herein includes an integer of preferably
- the "q" used herein includes an integer of preferably
- r and r' used herein independently include an integer of preferably 1 to 2.
- the "s and s' " used herein independently include an integer of preferably 0 and 1.
- t and t' used herein independently include an integer of preferably 1.
- the "u" used herein includes an integer of preferably
- the "v” used herein includes an integer of preferably
- the "Formulae (A-l) to (A-4) " used herein may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of preferably C - 6 alkyl group, hydroxy group, and Ci _ 6 alkoxy group at each substitutable position thereof .
- R 8 , R 9 and D are independently C x - 6 alkyl group, C 3 - 6 alkenyl group, C 3 _ 6 alkynyl group, C 3 . 8 monocyclic, C 7 - i o bicyclic or C 7 . 1 2 tricyclic cycloalkyl group, or C 5 _ 8 monocyclic or C 7 - 1 0 bicyclic cycloalkenyl group;
- the R 8 , R 9 and D may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of preferably Ci -4 alkyl group, hydroxy group, Ci_ 4 alkoxy group, Ci -4 haloalkyl group, and aryl group at each substitutable position thereof.
- R 8 , R 9 and D are independently -(CH 2 ) U - R 12 wherein u is an integer of 1 to 4; the alkylene chain may be optionally substituted with one or more substituents independently- selected from the group consisting of preferably C ⁇ . 6 alkyl group, hydroxy group, and C . 6 alkoxy group at each substitutable position thereof.
- R 13 is Ci . 6 alkyl group, C 3 .. 6 alkenyl group, C 3 - 6 alkynyl group, C 3 . 8 cycloalkyl group, or C 5 _ 8 cycloalkenyl group; the R 13 may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of preferably Ci- 4 alkyl group, hydroxy group, Ci -4 alkoxy group, Ci-4 haloalkyl group, Ci -4 haloalkoxy group, and halogen atom at each substitutable position thereof.
- R 16 is Ci . 6 alkyl group, C 3 . 6 alkenyl group, C 3 - 6 alkynyl group, C 3 - 8 cycloalkyl group, C 5 . 8 cycloalkenyl group, 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group, or 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group; the R 16 may be independently and optionally substituted with one or more , substituents independently-selected from the group consisting of preferably Ci -4 alkyl group, hydroxy group, Ci-4 alkoxy group, Ci- 4 haloalkyl group, Ci- haloalkoxy group, oxo group, aryl group, heteroaryl group, and halogen atom; and more preferably Ci- alkyl group, hydroxy group, Ci_ 4 alkoxy group, Ci -4 haloalkyl group, C
- R 16 is aryl group or heteroaryl group; the R 16 may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of preferably halogen atom, hydroxy group, C 1-4 alkyl group, C 1-4 alkoxy group, Ci- haloalkyl group, Ci- 4 haloalkoxy group, cyano group, and an optionally-substituted amino group; ' more preferably, halogen atom, Ci- alkyl group, Ci -4 alkoxy group, Ci- haloalkyl group, Ci -4 haloalkoxy group, and an optionally- substituted amino group; and even more preferably halogen atom, Ci- 4 alkyl group, Ci -4 alkoxy group, and an optionally- substituted amino group at each substitutable position thereof .
- R 19 and R 20 are taken together with the adjacent nitrogen atom to form a saturated or unsaturated 4- to 8-membered monocyclic nitrogen-containing heterocyclic group comprising additional 0 to 2 heteroatoms independently- selected from the group consisting of 1 to 2 nitrogen atoms, 1 oxygen atom and 1 sulfur atom; the formed ring may be optionally substituted with one or more substituents independently- selected from the group consisting of preferably Ci- alkyl group, hydroxy group, Ci-4 alkoxy group, oxo group and halogen atom at each substitutable position thereof.
- R 1 and R 15 are independently Ci - 6 alkyl group, G 3 - 6 alkenyl group, C 3 _ 6 alkynyl group, C 3 . 8 cycloalkyl group, C 5 . 8 cycloalkenyl group, 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group, 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group, C 2 - 6 alkanoyl group, Ci- 6 alkoxycarbonyl group, or Ci .
- the R 14 and R 15 may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of preferably Ci -4 alkyl group, hydroxy group, Ci -4 alkoxy group, oxo group, aryl group, heteroaryl group, and halogen atom; and more preferably Ci -4 alkyl group, hydroxy group, Ci -4 alkoxy group, and halogen atom at each substitutable position thereof.
- R and R are taken together with the adjacent nitrogen atom to form a saturated or unsaturated 4- to 9-membered monocyclic or 7- to 10-membered bicyclic nitrogen-containing heterocyclic group comprising additional 0 to 2 heteroatoms independently- selected from the group consisting of 1 to 2 nitrogen atoms, 1 oxygen atom and 1 sulfur atom;
- the formed ring may be optionally substituted with one or more substituents independently- selected from the group consisting of preferably C 1-4 alkyl group, hydroxy group, Ci- 4 alkoxy group, Ci -4 haloalkyl group, Ci-4 haloalkoxy group, oxo group, and halogen atom; and more preferably, Ci -4 alkyl group, hydroxy group, Ci- 4 alkoxy group, oxo group, and halogen atom at each substitutable position thereof.
- R 8 ' and R 9 ' are independently Ci . 6 alkyl group, C 3 _ 6 alkenyl group, C 3 . 6 alkynyl group, C 3 - 8 cycloalkyl group, C 5 - 8 cycloalkenyl group, 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group, or 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group;
- the R 8 ' and R 9 ' may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of preferably C 1-4 alkyl group, hydroxy group, Ci- 4 alkoxy group, Ci-4 haloalkoxy group, oxo group, aryl group, heteroaryl group, aryloxy group, and halogen atom; and more preferably C 1 - 4 alkyl group, hydroxy group, Ci- alkoxy group,
- R 8 and R 9 and a pair of R 8 ' and R 9 ' are independently taken together with the adjacent nitrogen atom to form a saturated or unsaturated 4- to 9- membered monocyclic or 7- to 10-membered bicyclic nitrogen- containing heterocyclic group comprising additional 0 to 2 heteroatoms independently- selected from the group consisting of 1 to 2 nitrogen atoms, 1 oxygen atom and 1 sulfur atom;
- the formed rings may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of preferably Ci - 4 alkyl group, and oxo group at each substitutable position thereof.
- R 1 0 , R 1 0 ' , R 11 and R 11 ' are independently Ci- 6 alkyl group, C 2 - 6 alkenyl group, C 2 - ⁇ alkynyl group, or Ci- 6 alkoxy group; the R 1 0 , R 1 0 ' , R 11 and R 11 ' may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of preferably Ci -4 alkyl group, hydroxy group, Ci-4 alkoxy group, Ci- 4 haloalkoxy group, oxo group, aryl group, heteroaryl group, aryloxy group, and halogen atom; and more preferably, C 1 -4 alkyl group, hydroxy group, Ci- alkoxy group, and halogen atom at each substitutable position thereof.
- R 10 and R 11 and a pair of R 10 ' and R 11 ' are independently taken together to form an optionally- substituted saturated or unsaturated 3- to 8- membered ring that may comprise 1 oxygen atom, which may be a bicyclic or a spiro compound with the ring to which the pair of R 10 and R 11 , or R 10 ' and R 11 ' is attached;
- the formed rings may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of preferably d.- alkyl group, hydroxy group, Ci - 4 alkoxy group, oxo group, and halogen atom at each substitutable position thereof.
- R 1 is Ci . 6 alkyl group, C 2 - 6 alkenyl group, C 2 - 6 alkynyl group, C 3 _ 8 cycloalkyl group, or C 5 _ 8 cycloalkenyl group; the R 1 may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of preferably Ci - 4 alkyl group, hydroxy group, C i - 4 alkoxy group, C 1 -4 haloalkyl group, Ci_ 4 haloalkoxy group, and halogen atom; and more preferably C 1-4 alkyl group, hydroxy group, and Ci-4 alkoxy group at each substitutable position thereof.
- R 2 is Ci . 6 alkyl group, C 2 - & alkenyl group, C 2 - 6 alkynyl group, C 3 - 8 cycloalkyl group, C 5 _ 8 cycloalkenyl group, Ci .
- the R 2 may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of preferably Ci -4 alkyl group, hydroxy group, Ci_ 4 alkoxy group, Ci-4 haloalkyl group, C i -4 haloalkoxy group, and halogen atom; and more preferably Ci_ 4 alkyl group, hydroxy group, and Ci-4 alkoxy group at each substitutable position thereof .
- R 3 is Ci . 6 alkyl group, C 2 - 6 alkenyl group, C 2 - 6 alkynyl group, C 3 - 8 cycloalkyl group, C 5 - 8 cycloalkenyl group, C x - 6 alkoxy group, Ci -4 haloalkyl group, Ci-4 haloalkoxy group, 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group, or 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group; the R 3 may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of preferably C 1- alkyl group, hydroxy group, Ci-4 alkoxy group, Ci- 4 haloalkyl group, C 1 - 4 haloalkoxy group, and halogen atom; and more preferably Ci_ 4 alkyl group, hydroxy group, and
- R 4 is Ci . 6 alkyl group, C 2 _ 6 alkenyl group, C 2 . 6 alkynyl group, C 3 - 8 cycloalkyl group, C 5 . 8 cycloalkenyl group, Ci .
- the R 4 may be independently and optionally substituted with one or more substituents independently- selected from the group consisting of preferably Ci -4 alkyl group, hydroxy group, Ci_ 4 alkoxy group, Ci-4 haloalkyl group, C 1-4 haloalkoxy group, and halogen atom; and more preferably Ci_ 4 alkyl group, hydroxy group, and Ci-4 alkoxy group at each substitutable position thereof.
- R 3 and R 4 are taken together to form a saturated or unsaturated 6- to 9-membered ring optionally comprising 1 oxygen atom; the formed ring may be optionally substituted with one or more substituents independently- selected from the group consisting of preferably Ci_ 4 alkyl group, hydroxy group, C 1-4 alkoxy group, oxo group, and halogen atom at each substitutable position thereof .
- R 5 and R 6 are independently Ci . 6 alkyl group, C 2 - 6 alkenyl group, C _ 6 alkynyl group, C 3 . 8 cycloalkyl group, C 5 . 8 cycloalkenyl group, Ci _ 6 alkoxy group, Ci- haloalkyl group, or Ci_ 4 haloalkoxy group;
- the R 5 and R 6 may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of preferably C 1-4 alkyl group, hydroxy group, Ci - 4 alkoxy group, C 1 - 4 haloalkyl group, Ci - 4 haloalkoxy group, and halogen atom; and more preferably Ci_ 4 alkyl group, hydroxy group, and Ci- 4 alkoxy group at each substitutable position thereof.
- the compound of Formula (1) may encompass all tautomers, geometric isomers, stereoisomers and a mixture thereof depending on the types of substituents.
- the compound of Formula (1) with one or more chiral carbon atoms exists in the form of a diastereomer or optical isomer, and the present invention encompasses a mixture or an isolated one of the diastereomer or optical isomer.
- the present invention also includes an isotope- labeled compound of Formula (1) and a pharmaceutically acceptable salt thereof, wherein the isotope-labeled compound is the same as the compound of Formula (1) except that one or more atoms in the compound have an atomic mass or a mass number which is different from the typical atomic mass or mass number present in nature.
- the present compound includes an isotope of, for example, hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, bromine, and chlorine.
- the present compound includes isotopes such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 18 0, 17 0, 15 0, 18 F, 75 Br, 76 Br, 77 Br, 82 Br, and 36 CI.
- the present invention also includes the present compounds which comprise the above-mentioned isotopes and/or other isotopes of other atoms, and pharmaceutically acceptable salts thereof .
- a particular isotope- labeled compound of the present invention e.g. a compound comprising radioisotopes such as 11 C, 3 H and 18 F
- isotope-labeled compound of the present invention is useful, for example, in a tissue distribution assay of the medicament and/or substrate, and especially useful as a diagnostic agent to find out the localization of the 5-HT 4 receptor subtype which is a serotonin receptor.
- the isotopes of tritium (i.e. 3 H), carbon-11 (i.e. 11 C) , and 18 F are especially preferable because they can be easily manufactured and detected.
- these compounds are also useful to assess the density of the said receptor in each region of the central nervous system, and to assess the receptor occupancy obtained by using a certain concentration of these compounds. The results of the assessment are likely to be helpful in determining the dosage and dose of these compounds .
- these isotope-labeled compounds can also be used for studying the characteristics of diseases which could have not been diagnosed in the past.
- substitution with heavy isotopes such as deuterium, i.e. 2 H can provide some therapeutic benefits owing to increased metabolic stability (such as prolongation of in vivo half-life and decrease of the required dosage) , and thus the compound having heavy isotopes may be preferable in some situations.
- the pharmaceutically acceptable salt used herein includes an acid addition salt and a base addition salt.
- the acid addition salt includes an inorganic acid salt such as hydrochloride, hydrobromide , sulfate, hydrogen sulfate, hydroiodide, nitrate, and phosphate; and an organic acid salt such as citrate, oxalate, acetate, formate, propionate, benzoate, trifluoroacetate, fumarate, maleate, malonate, succinate, tartrate, hydrogen tartrate, lactate, malate, pyruvate, gluconate, saccharate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate, and pamoate [i.e.
- the base addition salt includes an inorganic base salt such as sodium salt, potassium salt, calcium salt, magnesium salt, and ammonium salt; and an organic base salt such as triethylammonium salt, triethanolammonium salt, pyridinium salt, and diisopropylammonium salt.
- the pharmaceutically acceptable salt may also include a basic amino acid salt such as alginate, aspartate, and glutamate; and an acidic amino acid salt.
- the salt used herein includes preferably hydrochloride, hydrobromide, sulfate, phosphate, citrate, fumarate, maleate, malonate, succinate, tartrate, lactate, malate, pyruvate, methanesulfonate, and benzenesulfonate .
- the compound of Formula (1) and a pharmaceutically acceptable salt thereof may be a solvate such as a hydrate or an ethanolate, and the hydrate and/or solvate are also included in the present compound.
- the compound of Formula (1) can be synthesized from a well-known compound by combining several well-known processes.
- the compound can be prepared as follows.
- r', s', u, A, B, U, V, W, X, Y, Z, R 3 , R 4 , R 5 , R 6 , R 10 ' , R 11' and R 13 are as defined above, and L 1 is a leaving group.
- the compound of Formula (1') can be prepared by reacting the compound of Formula (1-1) with the reactive derivative of Formula (1-2) in the presence of an appropriate additive such as a base.
- the reactive derivative of Formula (1-2) wherein L 1 is hydroxy group may include the carboxylic acid compound of Formula (1-3) : R 16 -COOH wherein R 16 is as defined above, and an alkyl ester thereof (in particular, a methyl ester) , an active ester thereof, an acid anhydride thereof, and a carboxylic halide thereof (in particular, a carboxylic chloride) .
- the carboxylic acid compound of Formula (1-3) may be reacted in the presence of a condensing agent such as 1,3- dicyclohexylcarbodiimide , 1 -ethyl - 3 - ( 3 -dimethylamino- propyl) carbodiimide hydrochloride, N / N'-carbonyldiimidazole, benzotriazol-l-yloxytris (dimethylamino) phosphonium hexa- fluorophosphate, N,N'-carbonyldisuccinimide, 1- ethoxy- carbonyl- 2 -ethoxy- 1, 2-dihydroquinoline, diphenylphosphoryl azide, and propanephosphonic anhydride.
- a condensing agent such as 1,3- dicyclohexylcarbodiimide , 1 -ethyl - 3 - ( 3 -dimethylamino- propyl) carbodiimide hydro
- Formula (1-3) specifically includes p-nitrophenyl ester, pentachlorophenyl ester, pentafludrophenyl ester, N- hydroxysuccinimide ester, N-hydroxyphthalimide ester, 1- hydroxybenzotriazole ester, 8-hydroxyquinoline ester, 2- hydroxyphenyl ester, etc.
- the acid anhydride of carboxylic acid compound of Formula (1-3) used herein may include a symmetrical acid anhydride or a mixed acid anhydride; and the mixed acid anhydride specifically includes a mixed acid anhydride with an alkyl chlorocarbonate such as ethyl chlorocarbonate and isobutyl chlorocarbonate, a mixed acid anhydride with an aralkyl chlorocarbonate such as benzyl chlorocarbonate, a mixed acid anhydride with an aryl chlorocarbonate such as phenyl chlorocarbonate, and a mixed acid anhydride with an alkanoic acid such as isovaleric acid and pivalic acid.
- an alkyl chlorocarbonate such as ethyl chlorocarbonate and isobutyl chlorocarbonate
- a mixed acid anhydride with an aralkyl chlorocarbonate such as benzyl chlorocarbonate
- a mixed acid anhydride with an aryl chlorocarbonate such as pheny
- the reactive derivative of Formula (1-2) may include the compound of Formula (1-4) :
- the compound of Formula (1-4) wherein L 1 is chlorine atom is commercially available, or can be prepared by reacting R 16 OH and phosgene, diphosgene or a phosgene equivalent such as triphosgene.
- the reactive derivative of Formula (1-2) may include the compound of Formula (1-5) :
- the reactive derivative of Formula (1-2) may include the compound of Formula (1-6) :
- the reaction of the compound of Formula (1-1) and the reactive derivative of Formula (1-2) can be carried out in the presence or absence of a solvent.
- the solvent used herein should be optionally selected depending on the types of starting compounds and other factors, and includes, for example, aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, cyclopentyl methyl ether; halogenated hydrocarbons such as methylene chloride and chloroform; ketones such as acetone and methyl ethyl ketone; ethyl acetate; acetonitrile ; N, N-dimethylformamide ; and dimethylsulfoxide . These solvents may be used alone or in a mixture of two or more .
- the reaction may be optionally carried out in the presence of a base.
- the base used herein includes specifically alkali hydroxides such as sodium hydroxide and potassium hydroxide; alkaline carbonates such as sodium carbonate and potassium carbonate; alkaline bicarbonates such as sodium bicarbonate and potassium bicarbonate; and organic bases such as triethylamine, tributylamine, diisopropylethylamine, and N-methylmorpholine .
- an excess amount of the compound may be used.
- the reaction temperature depends on the types of the starting compound used herein or other factors; and it is typically about -30°C to about 200 °C, and preferably about -10°C to about 150°C.
- the leaving group of L 1 used herein includes, for example, halogen atoms such as chlorine, bromine, and iodine; alkylsulfonyloxy groups such as methanesulfonyloxy group; and arylsulfonyloxy groups such as benzenesulfonyloxy group and p-toluenesulfonyloxy group; and preferably halogen atoms (in particular, chlorine and bromine) , methanesulfonyloxy, and p-toluenesulfonyloxy .
- halogen atoms such as chlorine, bromine, and iodine
- alkylsulfonyloxy groups such as methanesulfonyloxy group
- arylsulfonyloxy groups such as benzenesulfonyloxy group and p-toluenesulfonyloxy group
- halogen atoms in particular,
- r, s, r*, s', A, U, V, W, X, Y, Z, R 3 , R 4 , R 5 , R 6 , R 10 , R 11 , R 10' and R 11' are as defined above,
- L 2 is a protecting group which may be eliminated by hydrolysis or hydrogenolysis
- L 3 is -CH 2 -L 4 (wherein L 4 is a leaving group) or formyl group .
- r, s, r', s', A, U, V, W, X, Y, Z, R 3 , R 4 , R 5 , R 6 , R 10 , R 11 , R 10 ' and R 11 ' are as defined above,
- L 2 is a protecting group which may be eliminated by hydrolysis or hydrogenolysis .
- L 5 is oxo group or a leaving group.
- Step 1 and Step 3 are an alkylation step carried out by a substitution reaction in the presence or absence of a solvent.
- the solvent used herein should be optionally selected depending on the types of starting compounds, etc., and includes for example, aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, .
- cyclopentyl methyl ether, and dioxane halogenated hydrocarbons such as methylene chloride and chloroform; alcohols such as ethanol, isopropanol, and ethylene glycol ; ketones such as acetone and methyl ethyl ketone; ethyl acetate, acetonitrile; N, N-dimethylformamide; and dimethylsulfoxide .
- halogenated hydrocarbons such as methylene chloride and chloroform
- alcohols such as ethanol, isopropanol, and ethylene glycol
- ketones such as acetone and methyl ethyl ketone
- ethyl acetate, acetonitrile N, N-dimethylformamide
- dimethylsulfoxide .
- the reaction can be carried out in the presence of a base as appropriate, and the base used herein includes alkali hydroxides such as sodium hydroxide and potassium hydroxide; alkaline carbonates such as sodium carbonate and potassium carbonate; alkaline bicarbonates such as sodium bicarbonate and potassium bicarbonate; and organic bases such as triethylamine, tributylamine, diisopropylethylamine, and N-methylmorpholine .
- alkali hydroxides such as sodium hydroxide and potassium hydroxide
- alkaline carbonates such as sodium carbonate and potassium carbonate
- alkaline bicarbonates such as sodium bicarbonate and potassium bicarbonate
- organic bases such as triethylamine, tributylamine, diisopropylethylamine, and N-methylmorpholine .
- an excess amount of the compound may be used.
- the leaving groups of L 4 and L 5 include, for example, halogen atoms such as chlorine, bromine, and iodine; alkylsulfonyloxy groups such as methanesulfonyloxy group; and arylsulfonyloxy groups such as benzenesulfonyloxy group and p-toluenesulfonyloxy group; and preferably halogen atoms (in particular, chlorine and bromine) , methanesulfonyloxy, and p-toluenesulfonyloxy.
- L 4 and L 5 are chlorine or bromine
- the reaction smoothly proceeds by adding alkali metal iodides such as sodium iodide and potassium iodide.
- the reaction temperature depends on the types of the starting compound used herein or other factors; and it is typically about 0°C to about 200°C, preferably about 20°C to about 150°C.
- the compounds of Formula (2-2) and Formula (3-1) are commercially available, or may be prepared according to known methods.
- the compounds of Formula (2-2) and Formula (3-1) wherein L 4 and L 5 are a leaving group can be prepared from the corresponding alcohol derivatives of Formula (2 -2a) and Formula (3 -la) by converting the corresponding group into a leaving group according to conventional methods:
- r', s 1 , R 10 ' , R 11 ' and L 2 are as defined above; and L 4 and L 5 are a leaving group.
- the compound of Formula (2 -2a) can be reacted with carbon tetrachloride or carbon tetrabromide and triphenylphosphine to give a compound wherein L 4 is chlorine atom or bromine atom.
- the compound of Formula (2-2a) can be reacted with sulfonyl chloride compounds such as benzenesulfonyl chloride in the presence of a base to give a compound wherein L 4 is arylsulfonyloxy group or alkylsulfonyloxy group.
- Step 1 and Step 3 are a reductive alkylation step and can be, for example, carried out under the following conditions:
- the solvent used herein includes the solvents mentioned in the above-mentioned 1) .
- the acid used herein includes, for example, p-toluenesulfonic acid, hydrogen chloride, and titanium tetraisopropoxide .
- the reaction temperature is usually about 0°C to about 100 °C, and preferably about 20 °C to about 80°C.
- the compounds of Formula (2-2) and Formula (3-1) used herein are commercially available, or may be prepared according to known methods.
- the compounds of Formula (2-2) wherein L 3 is formyl group and Formula (3-1) wherein L 5 is oxo group can be prepared by oxidizing the corresponding alcohol derivatives of Formula (2-2) and Formula (3-la) according to conventional methods.
- the compounds of Formula (2 -2a) and Formula (3-la) can be oxidized with phosgene, dimethylsulfoxide and triethylamine .
- the compound of Formula (2-2) can also be prepared by reducing the corresponding carboxylic acid or an ester thereof according to conventional methods, and for example, by reducing the compound of Formula (2 -2b) with DIBAH (i.e. diisobutylaluminium hydride) .
- DIBAH i.e. diisobutylaluminium hydride
- the compound of Formula (2-2b) used herein is commercially available, or may be prepared according to known methods .
- Step 2 and Step 4 are a deprotection reaction.
- protecting groups which may be eliminated by hydrolysis include, for example, ethoxycarbonyl group, tert- butoxycarbonyl group, acetyl group, benzoyl group, trifluoroacetyl group, benzyloxycarbonyl group, 3- or 4- chlorobenzyloxycarbonyl group, triphenylmethyl group, methanesulfonyl group, and p-toluenesulfonyl group.
- the deprotection by hydrolysis can be carried out according to conventional methods, and for example, it may be carried out by contacting the protecting group with water in a suitable solvent under an acidic or basic condition.
- the solvent used herein includes, for example, alcohols such as methanol, ethanol , and isopropanol; acetonitrile; dioxane; water; and a mixture thereof.
- the acid used herein specifically includes mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, and sulfuric acid; and organic acids such as formic acid, acetic acid, trifluoroacetic acid, p-toluenesulfonic acid, and methanesulfonic acid.
- the base used herein specifically includes alkali hydroxides such as sodium hydroxide and potassium hydroxide; and alkaline carbonates such as sodium carbonate and potassium carbonate.
- the reaction temperature is usually about 0°C to about 150°C.
- protecting groups which may be eliminated by hydrogenolysis include, for example, benzyloxycarbonyl group, 3- or 4- chlorobenzyloxycarbonyl group, benzyl group, and 4- methoxybenzyl group.
- the deprotection by hydrogenolysis can be carried out according to conventional methods, and for example, it may be carried out by reacting the protecting group in a suitable solvent in the presence of a catalyst (such as palladium carbon and Raney nickel) , and in the presence of hydrogen or a hydrogen donor (such as ammonium formate and cyclohexene) .
- the solvent used herein includes, for example, alcohols such as ethanol and methanol, water, acetic acid, dioxane, tetrahydrofuran, ethyl acetate, and AT, N-dimethyIformamide .
- the reaction is carried out at a temperature of usually about 0°C to about 80 °C, under normal or high pressure.
- the compound of Formula (2-1) described in Processes 2 and 3 can be prepared by the methods of the following Processes 4 to 6.
- L 6 is a leaving group
- L 7 is hydroxy group or a leaving group .
- Step 1 is a cyanation step.
- the leaving group of L 6 used herein includes, for example, bromine and p- toluenesulfonyl group.
- the base used herein is one or a mixture of two or more bases selected from the group consisting of, for example, trimethylamine, triethylamine, DMAP (i.e. 4-JV, N-dimethylaminopyridine) , pyridine, potassium tert-butoxide, butyllithium, sodium hydride, lithium hexamethyldisilazide , and cesium carbonate.
- the reaction temperature is usually about -80°C to about 100°C, and preferably about 0°C to about 80°C.
- the solvent used herein includes, for example, aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, cyclopentyl methyl ether and dioxane; halogenated hydrocarbons such as methylene chloride and chloroform; alcohols such as ethanol, isopropanol, and ethylene glycol; ketones such as acetone and methyl ethyl ketone; ethyl acetate; acetonitrile; N, N-dimethylformamide; and dimethylsulfoxide .
- aromatic hydrocarbons such as benzene, toluene, and xylene
- ethers such as diethyl ether, tetrahydrofuran, cyclopentyl methyl ether and dioxane
- halogenated hydrocarbons such as methylene chloride and chloroform
- alcohols such as
- Step 2 is a reaction to obtain an amidinoxime compound by reacting cyano group with hydroxylamine.
- the reaction can be carried out in the presence of a base as appropriate, and the base specifically includes alkali hydroxides such as sodium hydroxide and potassium hydroxide; alkaline carbonates such as sodium carbonate and potassium carbonate; alkaline bicarbonates such as sodium bicarbonate and potassium bicarbonate; and organic bases such as triethylamine, tributylamine , diisopropylethylamine , and N- methylmorpholine .
- alkali hydroxides such as sodium hydroxide and potassium hydroxide
- alkaline carbonates such as sodium carbonate and potassium carbonate
- alkaline bicarbonates such as sodium bicarbonate and potassium bicarbonate
- organic bases such as triethylamine, tributylamine , diisopropylethylamine , and N- methylmorpholine .
- the solvent used herein includes, for example, aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, cyclopentyl methyl ether, and dioxane; halogenated hydrocarbons such as methylene chloride and chloroform; alcohols such as ethanol, isopropanol, and ethylene glycol; ketones such as acetone and methyl ethyl ketone; ethyl acetate; acetonitrile; N, N-dimethylformamide; dimethyl - sulfoxide; and water. These solvents may be used alone or in a mixture of two or more.
- the reaction temperature is usually about 0°C to about 150°C, and preferably 20°C to about 80 °C .
- Step 3 is a condensation step (Step 3-1) followed by a cyclization step (Step 3-2) .
- the compound of Formula (4-5) can be reacted with the reactive derivative of Formula (4-6) in the presence of a suitable additive agent such as a base to give the compound of Formula (4-7), and then the compound of Formula (4-7) can be cyclized to give the compound of Formula (4-8) .
- the reactive derivative of (4-6) includes a carboxylic acid compound, and an alkyl ester thereof (in particular, methyl ester) , an active ester thereof, an acid anhydride thereof and an acid halide thereof (including an acid derivative wherein the halide is replaced with another leaving group which is a halide equivalent) .
- the derivative (4-6) is a carboxylic acid compound (i.e.
- the reaction can be carried out in the presence of a condensing agent such as 1,3- dicyclohexylcarbodiimide , 1-ethyl- 3 - ( 3 -dimethylamino- propyl) carbodiimide hydrochloride, ⁇ , ⁇ ' -carbonyldiimidazole, benzotriazol-l-yloxytris (dimethylamino) phosphonium hexa- fluorophosphate, N, N' -carbonyldisuccinimide , 1-ethoxy- carbonyl-2-ethoxy-l, 2-dihydroquinoline, diphenylphosphoryl azide, and propanephosphonic anhydride.
- a condensing agent such as 1,3- dicyclohexylcarbodiimide , 1-ethyl- 3 - ( 3 -dimethylamino- propyl) carbodiimide hydrochloride, ⁇ , ⁇ ' -carbonyld
- the active ester specifically includes p-nitrophenyl ester, pentachlorophenyl ester, pentafluorophenyl ester, N- hydroxysuccinimide ester, N-hydroxyphthalimide ester, 1- hydroxybenzotriazole ester, 8-hydroxyquinoline ester, 2- hydroxyphenyl ester, etc.
- the acid anhydride specifically includes a symmetrical acid anhydride and a mixed acid anhydride.
- the mixed acid anhydride specifically includes a mixed acid anhydride with an alkyl chlorocarbonate such as ethyl chlorocarbonate and isobutyl chlorocarbonate, a mixed acid anhydride with an aralkyl chlorocarbonate such as benzyl chlorocarbonate, a mixed acid anhydride with an aryl chlorocarbonate such as phenyl chlorocarbonate, and a mixed acid anhydride with an alkanoic acid such as isovaleric acid and pivalic acid.
- the present reaction can be carried out in the presence or absence of a solvent.
- the solvent used herein should be optionally selected depending on the types of starting compounds, etc., and for example, aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, and cyclopentyl methyl ether; halogenated hydrocarbons such as methylene chloride and chloroform; ketones such as acetone and methyl ethyl ketone; ethyl acetate; acetonitrile ; N,N- dimethylformamide; and dimethylsulfoxide .
- aromatic hydrocarbons such as benzene, toluene, and xylene
- ethers such as diethyl ether, tetrahydrofuran, dioxane, and cyclopentyl methyl ether
- halogenated hydrocarbons such as
- the reaction can be carried out in the presence of a base as appropriate, and the base includes alkali hydroxides such as sodium hydroxide and potassium hydroxide; alkaline carbonates such as sodium carbonate and potassium carbonate; alkaline bicarbonates such as sodium bicarbonate and potassium bicarbonate; and organic bases such as triethylamine, tributylamine , diisopropylethylamine , and N-methylmorpholine .
- alkali hydroxides such as sodium hydroxide and potassium hydroxide
- alkaline carbonates such as sodium carbonate and potassium carbonate
- alkaline bicarbonates such as sodium bicarbonate and potassium bicarbonate
- organic bases such as triethylamine, tributylamine , diisopropylethylamine , and N-methylmorpholine .
- an excess amount of the compound may be used.
- the reaction temperature depends on the types of the starting compound used herein or other factors; and it is typically about -30°C to about 200°C, and preferably about -10°C to about 150°C.
- L 7 includes, for example, halogen atoms (such as chlorine, bromine, and iodine) and detachable groups like halogen atoms (e.g. alkylsulfonyloxy groups such as methanesulfonyloxy group, and arylsulfonyloxy groups such as benzenesulfonyloxy group and p-toluenesulfonyloxy group) .
- L 7 is preferably halogen atoms (in particular, chlorine and bromine) , methanesulfonyloxy group or trifluoromethane- sulfonyloxy group.
- the present reaction is carried out in the presence or absence of a solvent.
- the solvent used herein should be optionally selected depending on the types of starting compounds, etc., and for example, aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, and cyclopentyl methyl ether; halogenated hydrocarbons such as methylene chloride and chloroform; ketones such as acetone and methyl ethyl ketone; ethyl acetate; acetonitrile ; N, N- dimethylformamide; and dimethylsulfoxide .
- aromatic hydrocarbons such as benzene, toluene, and xylene
- ethers such as diethyl ether, tetrahydrofuran, dioxane, and cyclopentyl methyl ether
- halogenated hydrocarbons such as
- the reaction can be carried out in the presence of a base as appropriate, and the base includes alkali hydroxides such as sodium hydroxide and potassium hydroxide; alkaline carbonates such as sodium carbonate and potassium carbonate; alkaline bicarbonates such as sodium bicarbonate and potassium bicarbonate; and organic bases such as triethylamine , tributylamine, diisopropylethylamine, and N-methylmorpholine .
- alkali hydroxides such as sodium hydroxide and potassium hydroxide
- alkaline carbonates such as sodium carbonate and potassium carbonate
- alkaline bicarbonates such as sodium bicarbonate and potassium bicarbonate
- organic bases such as triethylamine , tributylamine, diisopropylethylamine, and N-methylmorpholine .
- an excess amount of the compound may be used.
- the reaction temperature depends on the types of the starting compound used herein or other factors; and it is typically about 0°C to about 200 °C, and preferably about 20°C to about 150°G.
- the compound of Formula (4-7) can be reacted in the presence or absence of a suitable additive agent such as a base to give the compound of Formula (4-8) .
- the present reaction can be carried out in the presence or absence of a solvent .
- the solvent used herein should be optionally selected depending on the types of starting compounds, etc., and includes, for example, aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, and cyclopentyl methyl ether; halogenated hydrocarbons such as methylene chloride and chloroform; ketones such as acetone and methyl ethyl ketone; ethyl acetate; acetonitrile; N,N- dimethylformamide ; dimethylsulfoxide; and acetic acid. These solvents may be used alone or in a mixture of two or more .
- the base used herein includes, for example, alkaline carbonates such as sodium carbonate and potassium carbonate; alkaline bicarbonates such as sodium bicarbonate and potassium bicarbonate; alkali acetates such as sodium acetate and potassium acetate; and organic bases such as triethylamine, tributylamine , diisopropylethylamine, N- methylmorpholine, tetrabutylammonium fluoride, and quaternary ammonium hydroxide salts (e.g. tetramethyl- ammonium hydroxide) .
- the reaction temperature depends on the types of the starting compound used herein or other factors; and it is typically about 0°C to about 200°C, preferably about 20°C to about 110°C.
- Step 4 is a deprotection reaction.
- the compound of Formula (4-8) can be deprotected in the same manner as in the above-described L 2 to give the compound of Formula (2- 1 ' ) .
- the compound of Formula (4-1) described in Process 4 is commercially available, or may be prepared according to known methods.
- the compound of Formula (4-1) wherein, for example, V is nitrogen atom and is carbon atom [i.e. the compound of (4-1 1 )] can be prepared by the following process:
- R 2 ,R 3 ,R 4 ,R 5 , and R 6 are as defined above, X is a halogen atom (for example, when R 3 is methyl group, R 3 -MgX means methyl Grignard reagent) .
- Step 1 is an addition reaction of Grignard reagent to nitrile group.
- the compound of Formula (5-1) can be reacted with R 3 -MgX, and the resultant imine can be hydrolyzed by an acid to give the compound of Formula (5-2) [0153]
- the solvent used herein should be optionally selected depending on the types of starting compounds, etc., and for example, hydrocarbons such as hexane and n-heptane; aromatic hydrocarbons such as benzene, toluene, and xylene; and ethers such as diethyl ether, tetrahydrofuran, dioxane, and cyclopentyl methyl ether.
- hydrocarbons such as hexane and n-heptane
- aromatic hydrocarbons such as benzene, toluene, and xylene
- ethers such as diethyl ether, tetrahydrofuran, dioxane, and cyclopentyl methyl ether.
- the acid used herein includes mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, and sulfuric acid; and preferably hydrochloric acid.
- the reaction temperature is usually about -80°C to about 120°C, and preferably about -40°C to about 60 °C.
- Step 2 the amino group of the compound of Formula (5-2) can be diazotized in the presence of an acid, and the resultant diazonium salt can be reduced to make an indazole ring to give the compound of Formula (4-1') .
- the acid used herein includes, for example, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, and tetrafluoroboric acid; and preferably hydrochloric acid, sulfuric acid, and tetrafluoroboric acid
- the diazotization agent used herein includes, for example, nitrite salts such as sodium nitrite and potassium nitrite, and nitrite esters such as pentyl nitrite and isoamyl nitrite; and preferably sodium nitrite.
- the reducing agent used herein includes, for example, tin (II) chloride, sodium sulfite, sodium nitrite, sodium dithionite, and sodium thiosulfate.
- the reaction temperature is usually about -40°C to about 80°C, and preferably about -20°C to about 20°C.
- the solvent used herein includes the above-mentioned acids, and additionally includes, for example, aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, cyclopentyl methyl ether, . and dioxane; halogenated hydrocarbons such as methylene chloride and chloroform; alcohols such as methanol, ethanol, isopropanol, and ethylene glycol; ethyl acetate; acetonitrile; and water.
- aromatic hydrocarbons such as benzene, toluene, and xylene
- ethers such as diethyl ether, tetrahydrofuran, cyclopentyl methyl ether, . and dioxane
- halogenated hydrocarbons such as methylene chloride and chloroform
- alcohols such as methanol, ethanol, isopropanol,
- Step 3 is Sugasawa reaction.
- the compound of Formula (5-3) can be reacted with a nitrile derivative (defined as R 3 -CN) in the presence of Lewis acid to give the compound of Formula (5-2) .
- the Lewis acid used herein includes, for example, zinc chloride, tin (IV) chloride, titanic chloride, aluminum chloride, boron trichloride, and gallium trichloride. These Lewis acids may be used alone or in a mixture of two or more .
- the Lewis acid used herein is preferably a combination of boron trichloride and aluminum chloride, or a combination of boron trichloride and gallium trichloride.
- the reaction temperature is usually about -20°C to about 200°C, preferably about -10°C to about 150°C.
- the solvent used herein includes, for example, aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, cyclopentyl methyl ether and dioxane; halogenated hydrocarbons such as methylene chloride, chloroform, and 1, 2-dichloroethane; ethyl acetate; acetonitrile ; and N, N-dimethylformamide . These solvents may be used alone or in a mixture of two or more .
- aromatic hydrocarbons such as benzene, toluene, and xylene
- ethers such as diethyl ether, tetrahydrofuran, cyclopentyl methyl ether and dioxane
- halogenated hydrocarbons such as methylene chloride, chloroform, and 1, 2-dichloroethane
- ethyl acetate ace
- the compound of Formula (1) can also be prepared by the following process in case that, for example, B is Formula ( B-2) ; and D is an optionally-substituted Ci - 6 alkyl group, an optionally-substituted C 3 - 6 alkenyl group, an optionally- substituted C 3 . 6 alkynyl group, an optionally- substituted C 3-8 monocyclic, C 7 -i 0 bicyclic or C 7 . i2 tricyclic cycloalkyl group, or an optionally- substituted C 5 -8 monocyclic or C7-10 bicyclic cycloalkenyl group [i.e. Compound ( 1 1 1 ) ] :
- L 5 is oxo group (provided that when L 5 is attached to the primary carbon atom of D, L 5 forms a formyl group with the attached carbon atom) or a leaving group.
- Step 1 is an alkylation reaction.
- the compound of Formula (2-1) and the compound of Formula (6-1) can be reacted in the same manner as in 1) Alkylation step of Processes 2 and 3 to give the compound of Formula ( 1 ' ' ) .
- Step 1 is a reductive alkylation reaction.
- the compound of Formula (2-1) and the compound of Formula (6-1) can be reacted in the same manner as in 2) Reductive alkylation step of Processes 2 and 3 to give the compound of Formula (1' ') .
- the compound of Formula (1) can also be prepared by the following process in case that, for example, B is Formula (B-2) and D is Formula (R 12 -3) [i.e. Compound (1' ")] :
- L 5 is oxo group [provided that when L 5 is attached to the primary carbon atom in Formula (7-1), L 5 forms a formyl group with the attached carbon atom] or a leaving group.
- Step 1 is an alkylation reaction.
- the compound of Formula (2-1) and the compound of Formula (7-1) can be reacted in the same manner as in 1) Alkylation step of Processes 2 and 3 to give the compound of Formula ( 1 1 1 1 ) .
- Step 1 is a reductive alkylation reaction.
- the compound of Formula (2-1) and the compound of Formula (7-1) can be reacted in the same manner as in 2) Reductive alkylation step of Processes 2 and 3 to give the compound of Formula (l 1 ' 1 ) .
- the compound of Formula (1) can also be prepared by the following process in case that, for example, X is nitrogen atom, Z is nitrogen atom, Y is oxygen atom, and U is carbon atom [i.e. Compound (l 1 1 1 ')] :
- A, B, D, V, W, R 3 , R 4 , R 5 , R 6 and L 7 are as defined above.
- Step 1-1 is a condensation reaction
- Step 1-2 is a subsequent cyclization reaction.
- the compound of Formula (4- 5) and the compound of Formula (8-1) can be condensed and then cyclized to give the compound of Formula (l 1 1 1 ') .
- the compound of Formula (1) can also be prepared by the following process in case that, for example, X is nitrogen atom, Z is nitrogen atom, Y is oxygen atom, U is carbon atom, A is Formula (A-3) , and B is Formula (B-l) [i.e. the compound of Formula (l 1 ''')] :
- L 5 and L 11 are independently oxo group (provided that when L 5 or L 11 is attached to the primary carbon atom, L 5 or L 11 forms a formyl group with the attached carbon atom) or a leaving group.
- Step 1 and Step 1 ' are a condensation reaction followed by a cyclization reaction.
- the compound of Formula 1 is a condensation reaction followed by a cyclization reaction.
- Step 2 and Step 2' is an alkylation reaction.
- the compound of Formula (9-2) can be reacted with the compound of Formula (9-3) or Formula (9-8) to give the compound of Formula ( I ' l i ' i ) or Formula (1-2), respectively.
- Step 2 and Step 2' are a reductive alkylation reaction.
- the compound of Formula (9-2) can be reacted with the compound of Formula (9-3) or Formula (9-8) to give the compound of Formula (l 1 1 1 ' ') or Formula (1-2) , respectively.
- Step 3 is a deprotection reaction.
- the compound of Formula (9-4) is deprotected in the same manner as in the above-mentioned L 2 to give the compound of Formula (9-5) .
- Step 4 and Step 5 are an alkylation reaction.
- the compounds of Formula (9-5) and Formula (9-6) , or the compounds of Formula (1-2) and Formula (9-7) can be reacted to give the compound of Formula (1-2) or Formula (1' 1 1 1 ') , respectively.
- Step 4 and Step 5 is a reductive alkylation reaction.
- the compounds of Formula (9-5) and (9-6) , or the compounds of Formula (1-2) and Formula (9-7) can be reacted to give the compound of Formula (1-2) or Formula (1' 1 1 ' ') , respectively.
- the desired compound can be obtained by protecting the groups except the reactive site, carrying out the reaction, and then deprotecting it.
- the protecting group used herein includes, for example, typical protecting, groups described in the above-mentioned Protective Groups in Organic Synthesis and the like.
- the protecting group of amine includes, for example, ethoxycarbonyl, tert-butoxycarbonyl , acetyl, and benzyl; and that of hydroxy group includes, for example, tri (loweralkyl) silyl, acetyl, and benzyl.
- the protecting groups can be introduced and deprotected according to commonly used methods in synthetic organic chemistry (for example, see, the above-mentioned Protective Groups in Organic Synthesis) or other similar methods.
- the functional groups of the intermediates and the desired compounds in each process mentioned above are modified appropriately, different compounds in the present invention can be prepared.
- the functional group can be modified according to conventional general-methods (for example, see, Comprehensive Organic Transformations, R.C. Larock, 1989) .
- the starting materials and the intermediates in each of the above processes are well-known compounds or can be synthesized from well-known compounds according to well- known methods .
- the intermediates and the desired compounds in each of the above processes can be isolated and purified according to commonly-used purification methods in synthetic organic chemistry such as neutralization, filtration, extraction, washing, drying, concentration, recrystallization, and various types of chromatography.
- the intermediates may be used in the next reaction without purification.
- optical isomers such as enantiomers, planar-chiral forms, and axially chiral forms used herein can be resolved/isolated by using well-known resolving steps (e.g. methods using an optically active column, and fractionated crystallization) in a suitable step in the above processes.
- optically active substances may also be used as a starting material herein.
- the compound may, for example, form a salt with an optically active acid (e.g. monocarboxylic acids such as mandelic acid, N- benzyloxyalanine, and lactic acid; dicarboxylic acids such as tartaric acid, o-diisopropylidene tartrate, and malic acid; and sulfonic acids such as camphorsulfonic acid and bromocamphorsulfonic acid) in an inert solvent (e.g.
- an optically active acid e.g. monocarboxylic acids such as mandelic acid, N- benzyloxyalanine, and lactic acid
- dicarboxylic acids such as tartaric acid, o-diisopropylidene tartrate, and malic acid
- sulfonic acids such as camphorsulfonic acid and bromocamphorsulfonic acid
- alcohol solvents such as methanol, ethanol, and 2-propanol
- ether solvents such as diethyl ether
- ester solvents such as ethyl acetate
- aromatic hydrocarbon solvents such as toluene; acetonitrile; and a mixed solvent thereof
- the compound may be optically resolved by forming a salt thereof with an optically active amine (e.g. organic amines such as oi-phenethylamine, kinin, quinidine, cinchonidine , cinchonine, and strychnine) .
- an optically active amine e.g. organic amines such as oi-phenethylamine, kinin, quinidine, cinchonidine , cinchonine, and strychnine
- the temperature for forming the salt may be in the range of room temperature to boiling point of the solvent. In order to improve the optical purity, it is desirable to once raise the temperature to around the boiling point of the solvent.
- the solvent containing the crystallized salt can be optionally cooled before the filtration to raise the yield thereof.
- the amount of the optically active acid or amine used herein is in the range of about 0.5 equivalent to about 2.0 equivalents, and preferably around 1 equivalent per the substrate .
- the crystal can be optionally recrystallized in an inert solvent (e.g.
- alcohol solvents such as methanol, ethanol, and 2-propanol
- ether solvents such as diethyl ether
- ester solvents such as ethyl acetate
- aromatic hydrocarbon solvents such as toluene; acetonitrile ; and a mixed solvent thereof
- the resultant salt can be treated with an acid or base in a conventional method to obtain a free form thereof .
- the compound of Formula (1) can be obtained in the form of a free base or acid addition salt, depending on the types of the functional group in the formula, selection of the starting compound, and treatments/conditions of the reaction.
- Such free base or acid addition salt can be transformed into the compound of Formula (I) according to conventional methods.
- the compound of Formula (1) can be treated with various acids by using conventional methods to obtain an acid addition salt thereof.
- the present compound when it is necessary to obtain a salt of the present compound, if the present compound is given in the form of a salt, the resultant salt can be directly purified.
- the present compound if the present compound is given in a free form, the compound can be transformed to a salt thereof according to a conventional method by dissolving or suspending the free form in a suitable organic solvent, and then adding an acid or base thereto.
- present compound and a pharmaceutically acceptable salt thereof may exist in an addition form with water or various solvents, which are also comprised in the present invention.
- present invention may encompass all tautomers of the present compound, all possible stereoisomers of the present compound, all optical isomers of the present compound, and all aspects of crystals of the present compound.
- the present compound or a pharmaceutically acceptable salt thereof has a strong affinity and agonistic activity for serotonin-4 receptor, which is explained below, and thus expected to be a useful medicament for patients suffering from diseases or symptoms which are desired and/or required to be treated with an agonistic action or partial agonistic action for serotonin-4 receptor.
- the diseases or symptoms which are desired and/or required to be treated with an agonistic action or partial agonistic action for serotonin-4 receptor include, for example, the following (i) to (v) :
- neuropsychiatric diseases such as Alzheimer-type dementia, Lewy body dementia, vascular dementia, depression, posttraumatic stress disorder (PTSD) , memory impairment, anxiety, and schizophrenia;
- digestive system diseases such as irritable bowel syndrome, atonic constipation, habitual constipation, chronic constipation, constipation induced by drugs (e.g. morphine and antipsychotic drugs) , constipation associated with Parkinson's disease, constipation associated with multiple sclerosis, constipation associated with diabetes mellitus, and constipation or dyschezia caused by contrast materials taken as a pretreatment for endoscopic examinations or barium enema X-ray examinations;
- drugs e.g. morphine and antipsychotic drugs
- digestive system diseases such as functional dyspepsia, acute/chronic gastritis, reflux esophagitis, gastric ulcer, duodenal ulcer, gastric neurosis, postoperative paralytic ileus, senile ileus, non-erosive reflux disease, NSAID ulcer, diabetic gastroparesis , postgastrectomy syndrome, and intestinal pseudoobstruction;
- digestive system symptoms such as the digestive system diseases mentioned in the above (ii) and (iii) , scleroderma, diabetes mellitus, anorexia in esophageal/biliary-tract diseases, nausea, emesis, bloating, epigastric discomfort, abdominal pain, heartburn, and belching; and
- the present compound or a pharmaceutically acceptable salt thereof is useful as a medicament for treating or preventing especially the neuropsychiatric diseases such as Alzheimer-type dementia mentioned in the above (i) because the compound shows an excellent 5-HT 4 receptor agonist activity and brain penetration.
- the present compound or a pharmaceutically acceptable salt thereof may be orally or parenterally administered (e.g. intravenous or subcutaneous administration; infusions; intramuscular injections; subcutaneous injections; intranasal formulations; eye-drops, suppositories; and transdermal formulations such as ointments, creams, and lotions) for medical use.
- a formulation for oral administration includes, for example, tablets, capsules, pills, granules, powders, liquids, syrups and suspensions; and a formulation for parenteral administration includes, for example, injectable aqueous or oleaginous suspensions, ointments, creams, lotions, aerosols, suppositories, and adhesive skin patches.
- formulations can be formulated by using conventionally-known techniques, and may comprise conventionally-acceptable carriers, excipients, binders, stabilizers, lubricants, disintegrants , etc.
- the formulation for injection may further comprise an acceptable buffer, solubilizing agent, isotonic agent, etc.
- the formulation may also optionally comprise flavoring agent .
- excipient used herein includes, for example, organic excipients such as sugar derivative (e.g. lactose, white soft sugar, glucose, mannitol, and sorbitol) ; starch derivatives (e.g. corn starch, potato starch, a-starch, dextrin, and carboxymethyl starch) ; cellulose derivatives (e.g. crystalline cellulose, low-substituted hydroxy- propylcellulose, hydroxypropyl methylcellulose , carboxy- methylcellulose , carboxymethyl cellulose calcium, and internally-cross-linked carboxymethylcellulose sodium) ; acacia; dextran; and pullulan; and inorganic excipients such as silicate derivatives (e.g.
- sugar derivative e.g. lactose, white soft sugar, glucose, mannitol, and sorbitol
- starch derivatives e.g. corn starch, potato starch, a-starch, dextrin, and carboxy
- phosphates e.g. calcium phosphate
- carbonates e.g. calcium carbonate
- sulfates e.g. calcium sulfate
- the lubricant used herein includes, for example, stearic acid; metallic stearate such as calcium stearate, and magnesium stearate; talc; colloid silica; waxes such as VEEGUM and spermaceti; boric acid; adipic acid; sulfates such as sodium sulfate; glycol; fumaric acid; sodium benzoate; DL-leucine; fatty acid sodium salt; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; silicates such as anhydrous silicic acid and silicic acid hydrate; and the above-mentioned starch derivatives .
- stearic acid metallic stearate such as calcium stearate, and magnesium stearate
- talc colloid silica
- waxes such as VEEGUM and spermaceti
- boric acid adipic acid
- sulfates such as sodium
- the binder used herein includes, for example, polyvinylpyrrolidone, macrogol, and the substances defined in the above-mentioned excipient.
- the disintegrant used herein includes, for example, the substances defined in the above-mentioned excipient, and chemically-modified starches/celluloses such as croscarmellose sodium, sodium carboxymethyl starch, and cross-linked polyvinylpyrrolidone.
- the stabilizer used herein includes, for example, p- hydroxybenzoates such as methylparaben and propylparaben; alcohols such as chlorobutanol , benzyl alcohol, and phenylethyl alcohol; benzalkonium chloride; phenols such as phenol and cresol; thimerosal; dehydroacetic acid; and sorbic acid.
- the flavoring agent used herein includes, for example, commonly-used sweeteners, acidulants, and flavors.
- a tablet for oral administration may comprise an excipient together with various disintegrants as well as granulating binders. Furthermore, a lubricant is often very useful for tablet formulation.
- a similar type of the solid composition may be used as a bulking agent of a gelatin capsule which may be combined by various ingredients, preferably lactose (milk sugar) or high- molecular-weight polyethylene glycol.
- the active ingredient of aqueous suspension and/or elixir for oral administration may be combined with a diluent together with various sweetening agents, flavoring agents, coloring agents or dyes, or if desired, emulsifiers and/or suspending agents.
- the diluent includes water, ethanol, propylene glycol, glycerin and a mixture thereof.
- the diluent is conveniently included in feed or drinking water for animal in a concentration of 5 ppm to 5000 ppm, and preferably 25 ppm to 5000 ppm.
- a solution of the active ingredient for sterile injection may be typically prepared for parenteral administration (e.g. intramuscular, intraperitoneal, subcutaneous and intravenous use) .
- parenteral administration e.g. intramuscular, intraperitoneal, subcutaneous and intravenous use
- a solution of the present compound in, for example, sesame oil, peanut oil or aqueous propylene glycol may be used.
- the aqueous solution may be appropriately adjusted or buffered to a suitable pH, or prepared into an isotonic solution with a liquid diluent.
- the aqueous solution can also be used for intravenous injection.
- the oil solution can be also used for intra-articular, intramuscular and subcutaneous injections. All of these solutions may be prepared under sterile conditions by using conventional formulation techniques known to those skilled in the art.
- the present compound or a pharmaceutically acceptable salt thereof for the intranasal or inhalation administration may be provided in the solution or suspension form squeezed out or released by a patient from a pump spray vessel, or as an aerosol spray from a pressurized vessel or a nebulizer with using an appropriate propellant including, for example, dichlorodifluoromethane , trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide and other appropriate gases.
- a dosage unit in the pressurized aerosol can be determined by a bulb which provides a certain measured amount of the active ingredient.
- a solution or suspension of the active compound may be contained in the pressurized vessel or nebulizer.
- a capsule and cartridge for an inhaler or insufflator may be formulated to contain the present compound and a powder composition of appropriate powder bases including, for example, lactose and starch.
- the present compound or a pharmaceutically acceptable salt thereof may be also formulated in a composition for the anus such as a suppository or retention enema comprising conventional suppository bases including, for example, cacao butter and other glycerides.
- a dosage of the present compound or a pharmaceutically acceptable salt thereof depends on conditions, ages, administration methods, etc., and for example, the dosage is 0.01 mg (preferably 1 mg) as a lower limit and 5000 mg (preferably 500 mg) as an upper limit per day at one time or in several divided doses for adults for oral administration, preferably depending on conditions. It is expected to be effective in 0.01 mg (preferably 0.1 mg) as a lower limit and 1000 mg (preferably 30 mg) as an upper limit per day at one time or in several divided doses for adults for intravenous administration depending on conditions.
- present compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition or formulation containing the present compound may be optionally administered in combination with other medicaments in order to treat the diseases defined herein which are required to be treated with an agonistic action or partial agonistic action for serotonin-4 receptor.
- the present compound or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition or formulation containing the present compound is expected to show further efficacy in treating the various neuropsychiatric diseases mentioned in the above (i) , especially Alzheimer- type dementia, by combining at least one of the following medicaments:
- acetylcholinesterase inhibitors such as donepezil, galantamine, rivastigmine , SNX-001 and NP-61; cholinesterase inhibitors such as huperzine A; NMDA receptor antagonist such as memantine, dimebon and neramexane; 5-HT6 receptor antagonists such as PF-5212365 (SAM- 531) , SB-742457, LU-AE58054, AVN-322, PF-05212377 (SAM-760) and AVN101; a7nAChR agonists such as TC-5619, EVP- 6124 and GTS-21; ⁇ 4 ⁇ 2 ⁇ receptor agonists such as AZD-1446 and CHAN IX (varenicline ) ; nAChR agonists such as ABT-089; AMPA receptor agonists such as CX-717 and LY- 451395; histamine H3 antagonists such as ABT-288, SAR- 110894
- CDCI 3 Deuterated chloroform
- CDI ⁇ , ⁇ ' -carbonylimidazole TBAF: Tetrabutylammonium fluoride
- LiHMDS Lithium hexamethyldisilazide
- BINAP 2 , 2 ' -Bis (diphenylphosphino) - 1 , 1 1 -binaphthyl
- N Normal (e.g. 2 N HC1 means 2 normal of HC1)
- Condition FA (TFA or FA as an additive)
- Moving bed Al Distilled water (containing 0.075 % TFA, v/v)
- Moving bed A2 Distilled water (containing 0.2 % FA, v/v)
- Moving bed B Acetonitrile
- Moving bed Al Distilled water (containing 0.05% ammonia, v/v)
- Moving bed A Distilled water (containing 0.075 % TFA, v/v)
- Moving bed B Acetonitrile (containing 0.025 % TFA, v/v)
- Moving bed A Distilled water (containing 0.075 % TFA, v/v)
- Moving bed B Acetonitrile (containing 0.025 % TFA, v/v)
- Moving bed A Distilled water (containing 0.075 % TFA, v/v)
- Moving bed B Acetonitrile (containing 0.025 % TFA, v/v) [0195]
- Solution B 0.05 % formic acid/CH 3 CN
- the NMR measurements herein were carried out by using JEOL JNM-AL LA 300 and AL 400.
- Examples 002 to 012) were prepared in the same manner as in Reference Example 001 except that the 2-aminobenzonitrile and the isopropylmagnesium chloride were replaced with the corresponding starting compound and Grignard reagent defined as R 3 MgX wherein X is halogen atom, respectively.
- reaction solution was concentrated under reduced pressure, and the residue was purified by silica-gel chromatography (column; Hi-FlashTM, developing solvent: hexane / ethyl acetate) to give the title compound (1.66 g) .
- Reference Examples 034 to 043 were prepared in the same manner as in Reference Example 033 except that the 3-ethyl-6-fluoro-N' - hydroxy- IH-indazole-l-carboximidamide was replaced with the corresponding starting compound (which is described in Reference Examples 016 to 032) .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/005,659 US20140057895A1 (en) | 2011-06-07 | 2012-06-06 | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof |
BR112013030939A BR112013030939A2 (en) | 2011-06-07 | 2012-06-06 | indole and pyrrolopyridine derivative and pharmaceutical use thereof |
JP2013547047A JP2014510708A (en) | 2011-06-07 | 2012-06-06 | Indazole derivatives and pyrrolopyridine derivatives and their pharmaceutical use |
RU2013157374/04A RU2013157374A (en) | 2011-06-07 | 2012-06-06 | INDAZOLE AND PYROROLOPYRIDINE DERIVATIVE AND ITS PHARMACEUTICAL USE |
CA2833507A CA2833507A1 (en) | 2011-06-07 | 2012-06-06 | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof |
EP12796621.6A EP2718283A4 (en) | 2011-06-07 | 2012-06-06 | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof |
MX2013014427A MX2013014427A (en) | 2011-06-07 | 2012-06-06 | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof. |
CN201280025823.9A CN103748087A (en) | 2011-06-07 | 2012-06-06 | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof |
KR1020137032070A KR20140041519A (en) | 2011-06-07 | 2012-06-06 | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof |
AU2012267797A AU2012267797A1 (en) | 2011-06-07 | 2012-06-06 | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011-127688 | 2011-06-07 | ||
JP2011127688 | 2011-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012169649A1 true WO2012169649A1 (en) | 2012-12-13 |
Family
ID=47296200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/065052 WO2012169649A1 (en) | 2011-06-07 | 2012-06-06 | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US20140057895A1 (en) |
EP (1) | EP2718283A4 (en) |
JP (1) | JP2014510708A (en) |
KR (1) | KR20140041519A (en) |
CN (1) | CN103748087A (en) |
AU (1) | AU2012267797A1 (en) |
BR (1) | BR112013030939A2 (en) |
CA (1) | CA2833507A1 (en) |
MX (1) | MX2013014427A (en) |
RU (1) | RU2013157374A (en) |
TW (1) | TW201311674A (en) |
WO (1) | WO2012169649A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014092104A1 (en) * | 2012-12-12 | 2014-06-19 | 大日本住友製薬株式会社 | Oxadiazole derivative and pharmaceutical use of same |
US10328053B2 (en) | 2016-08-26 | 2019-06-25 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
EP3529245A4 (en) * | 2016-10-24 | 2020-12-23 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
EP3700934A4 (en) * | 2017-10-24 | 2021-10-27 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME02904B (en) | 2013-02-22 | 2018-04-20 | Pfizer | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus kinases (jak) |
EP3180344B1 (en) | 2014-08-12 | 2019-09-18 | Pfizer Inc | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
KR102140508B1 (en) | 2016-09-28 | 2020-08-03 | 경희대학교 산학협력단 | A composition for preventing or treating huntington's disease |
CN116836157A (en) * | 2022-03-25 | 2023-10-03 | 星希尔生物科技(上海)有限公司 | Oxadiazole derivative and preparation method and application thereof |
CN115417772A (en) * | 2022-09-26 | 2022-12-02 | 无锡双启科技有限公司 | Preparation method of 3-nitro-4-fluoroanisole |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001518906A (en) * | 1997-04-15 | 2001-10-16 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | Indazole amide compounds as serotonin-like agents |
JP2001518504A (en) * | 1997-10-07 | 2001-10-16 | イーライ・リリー・アンド・カンパニー | 5HT4 agonists and antagonists |
JP2007523175A (en) * | 2004-02-18 | 2007-08-16 | セラヴァンス, インコーポレーテッド | Indazole-carboxamide compounds as 5-HT4 receptor agonists |
JP2008525466A (en) * | 2004-12-22 | 2008-07-17 | セラヴァンス, インコーポレーテッド | Indazole-carboxamide compounds |
JP2009502770A (en) * | 2005-07-22 | 2009-01-29 | ファイザー株式会社 | Indazole carboxamide derivatives as 5HT4 receptor agonists |
JP2009543836A (en) * | 2006-07-14 | 2009-12-10 | グラクソ グループ リミテッド | Indole compounds |
WO2010086387A1 (en) * | 2009-01-30 | 2010-08-05 | Movetis Nv | 5-ht4 inhibitors for treating airway diseases, in particular asthma |
WO2012069917A1 (en) * | 2010-11-26 | 2012-05-31 | Lupin Limited | Bicyclic gpr119 modulators |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014001083B8 (en) * | 2011-09-19 | 2022-06-14 | Suven Life Sciences Ltd | Compound, process for preparing a compound, pharmaceutical composition, use of the pharmaceutical composition and use of the compound |
-
2012
- 2012-06-06 WO PCT/JP2012/065052 patent/WO2012169649A1/en active Application Filing
- 2012-06-06 US US14/005,659 patent/US20140057895A1/en not_active Abandoned
- 2012-06-06 EP EP12796621.6A patent/EP2718283A4/en not_active Withdrawn
- 2012-06-06 KR KR1020137032070A patent/KR20140041519A/en not_active Application Discontinuation
- 2012-06-06 MX MX2013014427A patent/MX2013014427A/en unknown
- 2012-06-06 AU AU2012267797A patent/AU2012267797A1/en not_active Abandoned
- 2012-06-06 BR BR112013030939A patent/BR112013030939A2/en not_active IP Right Cessation
- 2012-06-06 RU RU2013157374/04A patent/RU2013157374A/en not_active Application Discontinuation
- 2012-06-06 JP JP2013547047A patent/JP2014510708A/en active Pending
- 2012-06-06 CA CA2833507A patent/CA2833507A1/en not_active Abandoned
- 2012-06-06 CN CN201280025823.9A patent/CN103748087A/en active Pending
- 2012-06-07 TW TW101120435A patent/TW201311674A/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001518906A (en) * | 1997-04-15 | 2001-10-16 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | Indazole amide compounds as serotonin-like agents |
JP2001518504A (en) * | 1997-10-07 | 2001-10-16 | イーライ・リリー・アンド・カンパニー | 5HT4 agonists and antagonists |
JP2007523175A (en) * | 2004-02-18 | 2007-08-16 | セラヴァンス, インコーポレーテッド | Indazole-carboxamide compounds as 5-HT4 receptor agonists |
JP2008525466A (en) * | 2004-12-22 | 2008-07-17 | セラヴァンス, インコーポレーテッド | Indazole-carboxamide compounds |
JP2009502770A (en) * | 2005-07-22 | 2009-01-29 | ファイザー株式会社 | Indazole carboxamide derivatives as 5HT4 receptor agonists |
JP2009543836A (en) * | 2006-07-14 | 2009-12-10 | グラクソ グループ リミテッド | Indole compounds |
WO2010086387A1 (en) * | 2009-01-30 | 2010-08-05 | Movetis Nv | 5-ht4 inhibitors for treating airway diseases, in particular asthma |
WO2012069917A1 (en) * | 2010-11-26 | 2012-05-31 | Lupin Limited | Bicyclic gpr119 modulators |
Non-Patent Citations (1)
Title |
---|
DATABASE REGISTRY [online] XP003032808, Database accession no. 1002158-87-3 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014092104A1 (en) * | 2012-12-12 | 2014-06-19 | 大日本住友製薬株式会社 | Oxadiazole derivative and pharmaceutical use of same |
US10328053B2 (en) | 2016-08-26 | 2019-06-25 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
US10874640B2 (en) | 2016-08-26 | 2020-12-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
EP3529245A4 (en) * | 2016-10-24 | 2020-12-23 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
EP3700934A4 (en) * | 2017-10-24 | 2021-10-27 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
US11420974B2 (en) | 2018-02-26 | 2022-08-23 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
US11452711B2 (en) | 2020-09-03 | 2022-09-27 | Pfizer Inc. | Nitrile-containing antiviral compounds |
US11541034B2 (en) | 2020-09-03 | 2023-01-03 | Pfizer Inc. | Nitrile-containing antiviral compounds |
Also Published As
Publication number | Publication date |
---|---|
BR112013030939A2 (en) | 2016-12-06 |
MX2013014427A (en) | 2014-01-23 |
EP2718283A1 (en) | 2014-04-16 |
AU2012267797A2 (en) | 2014-05-22 |
EP2718283A4 (en) | 2014-10-29 |
US20140057895A1 (en) | 2014-02-27 |
KR20140041519A (en) | 2014-04-04 |
CN103748087A (en) | 2014-04-23 |
RU2013157374A (en) | 2015-07-20 |
AU2012267797A1 (en) | 2014-01-09 |
CA2833507A1 (en) | 2012-12-13 |
JP2014510708A (en) | 2014-05-01 |
TW201311674A (en) | 2013-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012169649A1 (en) | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof | |
JP2013010719A (en) | Benzimidazolone and oxindole derivative, and pharmaceutical application of them | |
AU2015330141B2 (en) | Spirodiamine derivatives as aldosterone synthase inhibitors | |
DK2545045T3 (en) | PIPERIDINE-4-YL-azetidine derivatives AS JAK1 INHIBITORS | |
KR101949624B1 (en) | Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds | |
JP5309131B2 (en) | Quinoline-carboxamide derivatives as P2Y12 antagonists | |
JP6715239B2 (en) | Substituted 2-azabicyclic compounds and their use as orexin receptor modulators | |
RU2448105C2 (en) | 2-aminobenzoxazole carboxamides as 5-ht3 modulators | |
KR20170045749A (en) | Smyd inhibitors | |
JP2023093623A (en) | 2-Oxoimidazolidine-4-carboxamides as NAV1.8 inhibitors | |
AU2018243691A1 (en) | Heterocyclic compound | |
KR20180016485A (en) | Positive allosteric modulator of muscarinic M2 receptor | |
AU2004231087A1 (en) | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | |
JP2014133739A (en) | Pharmaceutical comprising indazole derivative or pyrrolopyridine derivative | |
EP4041407A1 (en) | Aryl heterocyclic compounds as kv1.3 potassium shaker channel blockers | |
WO2014092104A1 (en) | Oxadiazole derivative and pharmaceutical use of same | |
CA3204318A1 (en) | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | |
TWI758325B (en) | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | |
CN114727991A (en) | Arylmethylene heterocyclic compounds as Kv1.3 potassium SHAKER channel blockers | |
TW202309017A (en) | 1h-pyrazole derivatives as sigma ligands | |
TW202233602A (en) | Pyrimidine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
TWI839355B (en) | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | |
WO2024026484A2 (en) | Cdk2 inhibitors and methods of using the same | |
WO2022152852A1 (en) | Antagonists of mrgx2 | |
TW202227404A (en) | Isoxazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12796621 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2013547047 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14005659 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2833507 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012796621 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20137032070 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/014427 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2012267797 Country of ref document: AU Date of ref document: 20120606 Kind code of ref document: A Ref document number: 2013157374 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013030939 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013030939 Country of ref document: BR Kind code of ref document: A2 Effective date: 20131202 |